Methods for differentiating pluripotent stem cells into cardiomyocytes

By partially replacing the culture medium during the activation-inhibition transition of WNT signaling, the problem of batch-to-batch variation and poor consistency in the generation of cardiomyocytes from pluripotent stem cells in existing technologies has been solved, achieving efficient and robust cardiomyocyte generation and advancing the therapeutic applications of regenerative medicine.

CN123125322APending Publication Date: 2026-11-17R P SCHERER TECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580016127.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-20
Filing Date
2025-02-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies struggle to efficiently and robustly generate cardiomyocytes from pluripotent stem cells (PSCs) while meeting GMP standards, resulting in batch-to-batch variability and poor consistency.

Method used

By partially replacing the culture medium during the transition from WNT signaling activation to inhibition, a certain level of exposure to WNT activators was maintained during WNT inhibition, thereby promoting cardiac specialization.

Benefits of technology

It improves the reproducibility and robustness of cardiomyocyte generation, overcomes batch-to-batch variation, and meets the needs of regenerative medicine and therapeutic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125322A_ABST
    Figure CN123125322A_ABST
Patent Text Reader

Abstract

This invention discloses a method for enhancing cardiomyocyte generation from induced pluripotent stem cells (iPSCs) by regulating the culture medium replacement process during the transition from WNT activation to WNT inhibition during differentiation. Unlike complete culture medium replacement, this innovative technique involves partial replacement, thereby enabling controlled exposure to WNT activators while introducing WNT inhibitors. This key improvement in the scheme significantly enhances the stability and efficiency of cardiomyocyte generation and reduces batch-to-batch variability. By finely tuning the culture medium replacement process, this method simplifies the preparation of cardiomyocytes for use in regenerative medicine, highlighting a crucial adjustment phase in culture conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Citation of relevant applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 555,818, filed February 20, 2024, pursuant to 35 USC § 119(e). The disclosure of the earlier application is considered to form part of the disclosure of this application and is incorporated herein by reference in its entirety. Technical Field

[0003] This invention relates generally to cardiomyocytes, and more specifically to a method for generating cardiomyocytes from pluripotent stem cells (PSCs). Background Technology

[0004] Cellular therapy methods can be broadly categorized based on their mechanisms of action as follows: transplantation of cells such as mesenchymal stromal cells (MSCs), which may provide benefits through immune modulation in largely undefined and paracrine ways; the use of therapeutic cells to specifically replace degenerated or damaged tissues, thereby restoring their function; and the engineering of cells to actively combat disease by secreting specific factors or targeting and eliminating unwanted cells, as seen in cancer immunotherapy. Induced pluripotent stem cells (iPSCs) have become a universal and versatile starting material for generating cells that meet these diverse therapeutic needs. The promise of iPSCs lies in their defining characteristics: the ability to self-renew, which is crucial for clonal isolation and expansion; and pluripotency, which provides the basis for generating virtually all cell types.

[0005] Over the years, specialized differentiation protocols based on iPSCs have been developed, enabling their application in clinical trials. One notable application is the differentiation of iPSCs into cardiomyocytes, a process that mimics early in vivo cardiomyogenesis. This involves guiding pluripotent stem cells (PSCs) into a mesodermal lineage, followed by cardiac specialization to generate cardiomyocytes. Various strategies have been employed to achieve this, including WNT pathway stimulation using small molecules such as CHIR99021 and BMP-driven protocols. These pathways may also synergize, thereby enhancing the robustness of cardiomyocyte differentiation. For example, the addition of BMP4 can synergize with WNT signaling to regulate key target genes in early differentiation stages. This synergy allows for the use of lower effective doses of WNT and BMP agonists, thus improving efficiency and consistency across experiments.

[0006] However, the transition from laboratory to clinical settings presents significant challenges, particularly in meeting the stringent Good Manufacturing Practice (GMP) requirements for Advanced Therapeutic Pharmaceutical Products (ATMP). Many current iPSC operating protocols, primarily developed in academic settings, struggle to comply with GMP standards, which demand rigorous quality certification of suppliers, equipment, and critical reagents, preferably GMP quality. These standards aim to streamline ATMP manufacturing workflows and ensure inter-laboratory consistency, as failure to meet GMP compliance can lead to extensive investigations and corrective actions.

[0007] Most existing differentiation schemes exhibit complexity, such as being technically inefficient, inconsistent, or reliant on undefined, complex, or animal-derived components. These schemes may also involve equipment that is difficult to certify or is incompatible with GMP, and are often inefficient in terms of cost and process time.

[0008] Given these challenges, there is an urgent need to develop robust, efficient, and GMP-compliant methods for generating cardiomyocytes from PSCs. Such methods would reliably produce cardiomyocytes for therapeutic applications, overcoming current limitations and realizing the promise of PSC technology in regenerative medicine. Summary of the Invention

[0009] This invention identifies a key advancement in PSC differentiation into cardiomyocytes through a novel method of partially replacing the culture medium during the transition from WNT signaling activation to WNT signaling inhibition. This counterintuitive approach, departing from the conventional practice of reversing signaling pathway activity by completely replacing the culture medium, has been found to significantly enhance the reproducibility and robustness of cardiomyocyte generation. By maintaining a certain level of WNT activator exposure while initiating WNT inhibition, this technique promotes a more consistent and efficient cardiac specialization process. This invention asserts that this partial culture medium replacement strategy is crucial for overcoming batch-to-batch variability, thus laying the foundation for a truly reliable method in regenerative medicine and therapeutic applications.

[0010] In one aspect, the present invention provides a method for inducing pluripotent stem cells (PSCs) to differentiate into cardiomyocytes, comprising: a) exposing PSCs to a culture medium for one or more days, wherein the culture medium contains a WNT signaling pathway activator and: (i) a bone morphogenetic protein (BMP) signaling pathway activator; (ii) optionally a fibroblast growth factor (FGF) / extracellular signal-regulated kinase (ERK) signaling pathway activator; and (iii) optionally a TGF-β signaling pathway activator; and b) partially replacing the culture medium from a) with a culture medium containing a WNT signaling pathway inhibitor and culturing for another one or more days, thereby inducing PSCs to differentiate into cardiomyocytes.

[0011] As characterized and disclosed herein, activators and inhibitors of the FGF / ERK signaling pathway include (as a non-limiting example) signaling pathway ligands, small molecule activators, small molecule inhibitors, peptide activators, peptide inhibitors, antibodies, nucleic acid activators, nucleic acid inhibitors, etc., which activate or inhibit at least one component of the FGF signaling pathway, thereby producing corresponding activation or inhibition in cellular FGF signaling. In some aspects of this disclosure, activation of the FGF signaling pathway and / or the mitogen-activated protein kinase (MAPK) / ERK signaling pathway is achieved by inhibiting FGF signaling pathway inhibitors and / or MAPK / ERK signaling pathway inhibitors, including (as a non-limiting example) the use of inhibitory nucleic acids targeting FGF signaling pathway and / or MAPK / ERK signaling pathway inhibitors, or antibodies or small molecules targeting FGF signaling pathway inhibitors and / or MAPK / ERK signaling pathway inhibitors. In some embodiments, the FGF / ERK signaling pathway activator is FGF2. In some respects, activators of the FGF signaling pathway may also include activators or inhibitors of related signaling pathways, including (as a non-limiting example) the MAPK / ERK signaling pathway.

[0012] In some embodiments, the concentration range of the FGF / ERK signaling pathway activator or inhibitor is between about 2.5 ng / ml and 20 ng / ml. In some embodiments, the FGF / ERK signaling pathway activator is FGF2, with a concentration range of about 2.5 ng / ml to 20 ng / ml. In some embodiments, the concentration range of the FGF / ERK signaling pathway activator is 2.5 to 3 ng / ml, 3 to 4 ng / ml, 4 to 5 ng / ml, 5 to 6 ng / ml, 6 to 7 ng / ml, 7 to 8 ng / ml, 8 to 9 ng / ml, 9 to 10 ng / ml, 10 to 11 ng / ml, 11 to 12 ng / ml, 12 to 13 ng / ml, 13 to 14 ng / ml, 14 to 15 ng / ml, 15 to 16 ng / ml, 16 to 17 ng / ml, 17 to 18 ng / ml, 18 to 19 ng / ml, 19 to 20 ng / ml, or between any two concentrations mentioned above or herein. In some embodiments, the concentration of FGF2 is approximately 7.5 ng / ml.

[0013] As characterized and disclosed herein, activators and inhibitors of the transforming growth factor β (TGF-β) superfamily include (as a non-limiting example) signaling pathway ligands, small molecule activators, small molecule inhibitors, peptide activators, peptide inhibitors, antibodies, nucleic acid activators, nucleic acid inhibitors, etc., which activate or inhibit at least one component of the TGF-β signaling pathway, thereby producing corresponding activation or inhibition in cellular TGF-β signaling. In some aspects of this disclosure, activation of the TGF-β signaling pathway is achieved by inhibiting TGF-β signaling pathway inhibitors, including (as a non-limiting example) the use of inhibitory nucleic acids targeting TGF-β signaling pathway inhibitors, or antibodies or small molecules targeting TGF-β signaling pathway inhibitors. In some aspects, activators of the TGF-β signaling pathway may also include activators or inhibitors of related signaling pathways, including (as a non-limiting example) bone morphogenetic protein (BMP), ERK / MAPK, phosphatidylinositol 3-kinase (PI3K) / protein kinase B (Akt), and non-receptor tyrosine kinase 1 (SRC) signaling pathways. In some embodiments, the TGF-β signaling pathway activator comprises activin A. In some embodiments, the concentration of the TGF-β signaling pathway activator or inhibitor ranges from about 2.5 ng / ml to 20 ng / ml. In some embodiments, the concentration of the TGF-β signaling pathway activator ranges from about 2.5 ng / ml to 20 ng / ml. In some embodiments, the concentration range of the TGF-β signaling pathway activator is 2.5 to 3 ng / ml, 3 to 4 ng / ml, 4 to 5 ng / ml, 5 to 6 ng / ml, 6 to 7 ng / ml, 7 to 8 ng / ml, 8 to 9 ng / ml, 9 to 10 ng / ml, 10 to 11 ng / ml, 11 to 12 ng / ml, 12 to 13 ng / ml, 13 to 14 ng / ml, 14 to 15 ng / ml, 15 to 16 ng / ml, 16 to 17 ng / ml, 17 to 18 ng / ml, 18 to 19 ng / ml, 19 to 20 ng / ml, or between any two concentrations mentioned above or herein. In some embodiments, the concentration of activator A is approximately 7.5 ng / ml.

[0014] As characterized and disclosed herein, activators of the BMP pathway include (as a non-limiting example) BMP family ligands such as BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8, BMP9, BMP8b, BMP10, BMP11, and BMP15; alantolactone; FK506; isoliquiritigenin; and 4'-hydroxychalcone. In some embodiments, activation of the BMP pathway can be achieved by inhibiting BMP pathway inhibitors, including (as a non-limiting example) using inhibitory nucleic acids targeting BMP pathway inhibitors, or antibodies or small molecules targeting BMP pathway inhibitors. In some embodiments, the BMP pathway activator comprises BMP4. In some embodiments, the concentration range of the BMP pathway activator is from about 1 ng / ml to 10 ng / ml. In some embodiments, the concentration range of the BMP pathway activator is 1 to 2 ng / ml, 2 to 3 ng / ml, 3 to 4 ng / ml, 4 to 5 ng / ml, 5 to 6 ng / ml, 6 to 7 ng / ml, 7 to 8 ng / ml, 8 to 9 ng / ml, 9 to 10 ng / ml, or between any two concentrations mentioned above or herein. In some embodiments, the concentration of BMP4 is approximately 5 ng / ml. In some embodiments, the concentration of BMP4 is approximately 7.5 ng / ml.

[0015] In some embodiments, as characterized and described herein, the volume of culture medium replaced ranges from about 5% to 90%. In some embodiments, the volume of culture medium replaced in step b) is about 10%, 25%, 50%, or 75% of the culture medium in a). In some embodiments, the volume of culture medium replaced in step b) is about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% of the culture medium in a), or any percentage of the culture medium in a) between any two percentages mentioned above or herein. In some embodiments, the volume of culture medium replaced in step b) is about 25% of the culture medium in a).

[0016] As characterized and disclosed herein, activators of the WNT signaling pathway include (as a non-limiting example) CHIR99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarboxynitrile); WNT family ligands; RSPO co-agonists; lithium chloride; TDZD8 (4-benzyl-2-methyl- 1,2,4-Thiadiazolidine-3,5-dione); BIO-acetyl oxime ((2'Z,3'E)-6-bromoindorubin-3'-acetyl oxime); A1070722 (1-(7-methoxyquinoline-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea); HLY78 (4-ethyl-5,6-dihydro-5-methyl-[1,3]dioxacyclopentenyl[4,5-j]phenanthridine); CID 11210285 hydrochloride (2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine hydrochloride); WAY-316606; (hetero)arylpyrimidine; IQ1; QS11; SB-216763; and / or DCA. In some embodiments, activation of the WNT signaling pathway can be achieved by inhibiting a WNT signaling pathway inhibitor, including (as a non-limiting example) using an inhibitory nucleic acid targeting a WNT signaling pathway inhibitor, or an antibody or small molecule targeting a WNT signaling pathway inhibitor. In some aspects, the WNT signaling pathway activator is added to PSC cultures at a concentration between about 0.1 µM and 10 µM. In some embodiments, the WNT signaling pathway activator is added to PSC cultures at concentrations between 0.1 and 0.5 µM, 0.5 and 1.0 µM, 1.0 and 2.0 µM, 2.0 and 3.0 µM, 3.0 and 4.0 µM, 4.0 and 5.0 µM, 5.0 and 6.0 µM, 6.0 and 7.0 µM, 7.0 and 8.0 µM, 8.0 and 9.0 µM, and 9.0 and 10 µM, or between any two concentrations mentioned above or herein. In some embodiments, the WNT signaling pathway activator comprises CHIR99021. In some embodiments, the WNT signaling pathway activator is CHIR99021, with a concentration ranging from about 0.5 µM to about 1 µM. In some embodiments, the concentration of CHIR99021 is about 0.5 µM.

[0017] As characterized and disclosed herein, culture medium supplements include or exclude vitamins, proteins, and amino acids. In some embodiments, vitamin supplements include or exclude vitamin C as ascorbate, ascorbic acid, its salts, or derivatives thereof. In some embodiments, the culture medium contains ascorbate. In some embodiments, the ascorbate is 2-phosphate-L-ascorbic acid. In some embodiments, the culture medium optionally contains one or more salts or derivatives of 2-phosphate-L-ascorbic acid. In some embodiments, protein supplements include or exclude albumin, transferrin, fibronectin, aprotinin, and fetoglobulin. In some embodiments, the protein supplement is albumin. In some embodiments, the protein supplement is human serum albumin (HSA). In some embodiments, amino acid supplements include or exclude glutamine. In some embodiments, glutamine is L-glutamine. In some embodiments, vitamin supplements are ascorbate or 2-phosphate-L-ascorbic acid, or any salt or derivative thereof, at a concentration ranging from about 50 µM to 500 µM. In some embodiments, the vitamin supplement concentration ranges from 50 to 100 µM, 100 to 150 µM, 150 to 200 µM, 200 to 250 µM, 250 to 300 µM, 300 to 350 µM, 350 to 400 µM, 450 to 500 µM, or between any two concentrations mentioned above or herein. In some embodiments, the protein supplement is albumin, with a concentration range of about 0.5 mg / ml to 10 mg / ml. In some embodiments, the protein supplement concentration ranges from 0.5 to 1.0 mg / ml, 1.0 to 2.0 mg / ml, 2.0 to 3.0 mg / ml, 3.0 to 4.0 mg / ml, 4.0 to 5.0 mg / ml, 5.0 to 6.0 mg / ml, 6.0 to 7.0 mg / ml, 7.0 to 8.0 mg / ml, 8.0 to 9.0 mg / ml, 9.0 to 10 mg / ml, or between any two concentrations mentioned above or herein. In some embodiments, the amino acid supplement is glutamine, with a concentration range of about 0.2 mM to 4 mM. In some embodiments, the amino acid supplement concentration ranges from 0.2 to 0.5 mM, 0.5 to 1.0 mM, 1.0 to 2.0 mM, 2.0 to 3.0 mM, 3.0 to 4.0 mM, or between any two concentrations mentioned above or herein. In some embodiments, the culture medium from a) and / or b) further comprises 2-phosphate-L-ascorbic acid and / or albumin, and optionally L-glutamine. In some embodiments, the culture medium is supplemented with about 250 µM 2-phosphate-ascorbic acid and / or about 5 mg / ml albumin, and optionally supplemented with about 2 mM L-glutamine.

[0018] In some embodiments, the contact in a) i.e., the growth of PSCs in the presence of WNT and BMP signaling pathway activators, lasts for at least 2 days. In some embodiments, the contact in a) lasts for at least 1, 2, 3, 4, 5, 6, 7, or 8 days or more, or for any duration between any two of the days described above or herein. In some embodiments, the contact in a) lasts for 1 day. In some embodiments, the contact in a) lasts for 2 days. In some embodiments, the contact in a) lasts for 4 days. In some embodiments, the contact in a) lasts for 5 days. In some embodiments, the contact in a) lasts for 6 days. In some embodiments, the contact in a) lasts for 7 days. In some embodiments, the contact in a) lasts for 8 days. In some embodiments, the contact in a) lasts for more than 8 days.

[0019] In some embodiments, the incubation in b) is performed for 2 to 5 days after the medium in a) that contacted the PSCs is partially exchanged with the medium containing the WNT signaling pathway inhibitor. In some embodiments, the incubation in b) is performed for 1, 2, 3, 4, or 5 days. In some embodiments, the incubation in b) is performed for more than 5 days. In some embodiments, the incubation in b) is performed for at least 1, 2, 3, 4, 5, 6, 7, or 8 days or more, or for any duration between any two of the days described above or herein. In some embodiments, the incubation in b) is performed for 1 day. In some embodiments, the incubation in b) is performed for 2 days. In some embodiments, the incubation in b) is performed for 4 days. In some embodiments, the incubation in b) is performed for 5 days. In some embodiments, the incubation in b) is performed for 6 days. In some embodiments, the incubation in b) is performed for 7 days. In some embodiments, the incubation in b) is performed for 8 days. In some embodiments, the incubation in b) is performed for more than 8 days. In some implementations, the incubation in b) is carried out for 1 to 2 days, 1 to 3 days, 1 to 4 days, 1 to 5 days, 1 to 6 days, 1 to 7 days, 1 to 8 days or more than 8 days, or for any duration between any two of the days described above or herein.

[0020] As characterized and disclosed herein, inhibitors of the WNT signaling pathway include (as a non-limiting example) C-59 (4-(2-methyl-4-pyridyl)-N-[4-(3-pyridyl)phenyl]phenylacetamide), DKK1, IWP2 (N-(6-methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]acetamide), Ant1.4Br Ant1,4CI, Niclosamide, apicularen, bafilomycin, XAV939 (3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one), IWR1 (4-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methylene-2H-isoindole-2) -N-8-quinolinyl-benzamide), NSC668036 (N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-(2S)-2-hydroxy-3-methylbutyryl-L-alanine-(1S)-1-carboxy-2-methylpropyl ester hydrate), 2,4-diamino-quinazolin, quercetin, ICG-001 ((6S,9aS)-hexahydro-6-[(4-hydroxyphenyl)methyl]-8- (1-Naphthylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-formamide), PKF115-584, BML-284 (2-amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3-methoxyphenyl)pyrimidine), FH-535, iCRT-14, JW-55, JW-67, antibodies against WNT and WNT receptors, and WNT-inhibiting nucleic acids. In some embodiments, inhibition of the WNT signaling pathway can be achieved by inhibiting WNT signaling pathway activators, including (as a non-limiting example) using inhibitory nucleic acids targeting WNT signaling pathway activators, or antibodies or small molecules against WNT signaling pathway activators. In some embodiments, the WNT signaling pathway inhibitor is selected from IWP2, IWR1, or C-59. In some embodiments, the concentration of the WNT signaling pathway inhibitor is at least 0.1 µM.In some embodiments, WNT signaling pathway inhibitors are added to PSC cultures at the following concentrations: 0.05 to 0.06 µM, 0.06 to 0.07 µM, 0.07 to 0.08 µM, 0.08 to 0.09 µM, 0.09 to 0.1 µM, 0.1 to 0.2 µM, 0.2 to 0.3 µM, 0.3 to 0.4 µM, 0.4 to 0.5 µM, 0.5 to 0.6 µM, 0.6 to 0.7 µM, 0.7 to 0.8 µM, 0.8 to 0.9 µM, 0.9 to 1 µM, 1.0 to 2.0 µM, 2.0 to 3.0 µM, 3.0 to 4.0 µM, 4.0 to 5.0 µM, 5.0 to 6.0 µM, 6.0 to 7.0 µM, 7.0 to 8.0 µM, and 8.0 to 9.0 µM. The concentration may be µM, 9.0 to 10 µM, or between any two concentrations described above or herein. In some embodiments, the concentration of the WNT signaling pathway inhibitor is approximately 2 µM. In some embodiments, C-59, IWP2, IWR1, or a combination thereof is approximately 2 µM.

[0021] In some embodiments, cardiomyocytes express maturity markers approximately 4 weeks after differentiation. In some embodiments, cardiomyocytes express maturity markers approximately 5 weeks after differentiation. In some embodiments, cardiomyocytes express maturity markers approximately 6 weeks after differentiation. In some embodiments, cardiomyocytes express maturity markers more than approximately 6 weeks after differentiation.

[0022] As described and disclosed herein, cardiomyocyte maturation markers include (as a non-limiting example) CAS12, S100A4, CASQ1, ADRB1, ADRB2, ATP2A2, RYR2, PLN, JPH2, CAMK2D, ATP1A3, KCNJ2, CACNA2D1, KCNQ1, SCN5A, KCNE1, SLC8A1, KCNH2, SCN4B, KCNE5, MYH6, MYL2, TNNI3, MYM2, MYH7, TPM1, MYL3, TNNC1, TNNT2, ACTC1, LPL, ACOX1, PPARA, PPARD, ACAT1, ACADVL, DGAT1, PPARGC1A, HADHB, and ACSL1. In some embodiments, maturation markers include MYL2, MYH7, and / or KCNQ1.

[0023] In some implementations, cardiomyocyte differentiation is carried out in cultures selected from the following: two-dimensional culture, three-dimensional culture, suspension culture, and adherent culture.

[0024] In some implementations, the culture is a culture plate, microcarrier beads, or a mesh matrix.

[0025] In some embodiments, cardiac troponin T (cTnT) positive cells are observed 8 days after differentiation. In some embodiments, cTnT positive cells account for at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the PSCs after at least 8 days of differentiation. In some embodiments, cardiac troponin T (cTnT) positive cells account for at least 80% of the PSCs after 9 days of differentiation.

[0026] In some implementations, the culture medium from a) and b) is Knockout-DMEM or IMDM.

[0027] In some implementations, the PSC is a human PSC (hPSC).

[0028] In some implementations, hPSCs are human induced pluripotent stem cells (hiPSCs) or human embryonic stem cells (hESCs).

[0029] In one aspect, the present invention provides a method for inducing cardiomyocyte differentiation from pluripotent stem cells (PSCs), comprising: a) contacting PSCs with an iPSC culture medium for at least one day, wherein the iPSC culture medium contains a Rho-associated kinase (ROCK) inhibitor, the inhibitor being any ROCK inhibitor characterized in this disclosure, to obtain ROCK inhibitor-cultured cells; b) contacting the ROCK inhibitor-cultured cells with a mesotherapy induction medium for one or more days, wherein the mesotherapy induction medium comprises: (i) a WNT signaling pathway activator, which may be any WNT signaling pathway characterized in this disclosure. (ii) an activator; (iii) a bone morphogenetic protein (BMP) signaling pathway activator, which may be any BMP signaling pathway activator characterized in this disclosure; (iv) optionally an FGF / ERK signaling pathway activator, which may be any FGF / ERK signaling pathway activator characterized in this disclosure; and (iv) optionally a TGF-β signaling pathway activator, which may be any TGF-β signaling pathway activator characterized in this disclosure; and (c) partially exchanging the culture medium from a) with a culture medium containing a WNT signaling pathway inhibitor and culturing for one or more days to induce PSC differentiation into cardiomyocytes.

[0030] As described and disclosed herein, ROCK inhibitors include (as non-limiting examples) Y-27632, ripasudil, netarsudil, chroman 1, Y39983, Wf-536, SLx-2119, azabenzimidazole-aminofurazans, DE-104 olefins, isoquinolines, indazoles, pyridine olefin derivatives, H-1152P, XD-4000, HMN-1152, and ROKα. 4-(1-aminoalkyl)-N-(4-pyridyl)cyclohexane-formamides, rhostatin, BA-210, BA-207, BA-285, BA-1037, BA-215, Ki-23095, VAS-012, quinazoline, GSK-269962, and their salts, including Y-27632 dihydrochloride, H-1152 dihydrochloride, fasudil hydrochloride, SR-3677 dihydrochloride, glycyl-H-1152 dihydrochloride, SB-772077B dihydrochloride, TC-S-7001, RKI-1447 dihydrochloride, and OXA-06 dihydrochloride.

[0031] In some embodiments, the concentration of the ROCK inhibitor is between about 1 µM and about 15 µM. In some embodiments, the ROCK inhibitor is Y-27632 at a concentration of about 10 µM. In some embodiments, the concentration range of the ROCK inhibitor is 1.0 to 2.0 µM, 2.0 to 3.0 µM, 3.0 to 4.0 µM, 4.0 to 5.0 µM, 5.0 to 6.0 µM, 6.0 to 7.0 µM, 7.0 to 8.0 µM, 8.0 to 9.0 µM, 9.0 to 10 µM, 10 to 11 µM, 11 to 12 µM, 12 to 13 µM, 13 to 14 µM, 14 to 15 µM, or between any two concentrations described above or herein.

[0032] Incorporated by reference

[0033] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the extent that each individual publication, patent, or patent application is specifically and individually designated as incorporated by reference. Furthermore, all documents referenced or mentioned in this document, together with any manufacturer's instructions, descriptions, product specifications, and product information for any product mentioned herein or incorporated herein by reference, are hereby incorporated by reference and are applicable in the practice of this invention. More specifically, all referenced documents are incorporated by reference to the extent that each individual document is specifically and individually designated as incorporated by reference. The full disclosure of these publications is hereby incorporated by reference to this application to more fully describe the prior art to which this application pertains. Disclosed references are also individually and specifically incorporated by reference to the material contained in sentences discussed therein or to which reliance is placed. U.S. Provisional Patent Application 63 / 555,818 is incorporated herein by reference as if fully set forth herein. Attached Figure Description

[0034] The novel features of the invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the invention can be obtained by referring to the following detailed description of illustrative embodiments, along with the accompanying drawings, which utilize the principles of the invention. The drawings include: Figure 1A An optimized cardiac induction protocol based on initial co-stimulation of the FGF, TGFβ, BMP, and WNT pathways is schematically illustrated. Differentiation begins at (not after) EB formation. F: FGF / ERK pathway stimulation; T: TGFβ pathway stimulation; B: BMP pathway stimulation; W: stimulation of the classical WNT pathway; αW: inhibition of classical WNT signaling. ITS: insulin / transferrin / selenium supplementation; Y: Rho-associated kinase (ROCK) inhibitor Y-27632 (promotes hPSC cell survival); AscP: L-ascorbic acid 2-phosphate; HSA: human serum albumin; Gln: L-glutamine; KO-DMEM: Knockout™-DMEM.

[0035] Figure 1B The results of cardiac differentiation assessments in 10 independent experiments are shown using the optimized protocol (hollow dots) and the semi-optimized protocol (black dots). The difference between the two is that in the left figure, partial culture medium replacement (< 75%) occurred from the pathway stimulation to inhibition phase, while in the semi-optimized case, culture medium exchange was > 75%.

[0036] Figure 1C The titration results of the 2-phosphate-L-ascorbic acid supplement are shown.

[0037] Figure 2 This demonstrates the importance of partial culture medium replacement from the WNT pathway stimulation phase to the WNT pathway inhibition phase. Comparative flow cytometry data from various independent experiments show a wide range of different amounts of culture medium exchange. Note that the most robust differentiation results, i.e., high and consistent cardiomyocyte yields across independent experiments, are obtained with 25% or less culture medium exchange.

[0038] Figure 3A The results show that co-stimulation with BMP and WNT (without additional FGF / TGFβ activation) achieves superior cardiomyocyte differentiation compared to WNT stimulation alone (n=2-10 per data point).

[0039] Figure 3B The dependence of the BMP+WNT regimen on cell titer is shown (flow cytometry data).

[0040] Figure 3C Numerical representation of a grid titration heatmap used to optimize cardiac mesodermal-induced BMP4 and CHIR99021 concentrations is shown. Note that WNT activation alone is inferior to co-stimulation of the BMP and WNT pathways.

[0041] Figure 4A The titration results show the optimal combined dosage of FGF2 and activator A supplements.

[0042] Figure 4B The results showed that adding more FGF and TGFβ pathway stimulation made the protocol more reliable in terms of cell titer dependence (n=6-8; shedding count 0%).

[0043] Figure 5 A comparison of different protocol variations is shown. The figures represent % cTnT values ​​obtained by flow cytometry, indicating the purity of the obtained iPSC-cardiomyocytes. Note the flexibility in the duration of pathway stimulation (tested for 1 or 2 days). As an alternative to treating dissociated hPSCs during 3D aggregate formation (first 4 rows), pre-formation in hPSC medium is also possible. Overall, the data suggest that WNT stimulation alone may be sufficient to initiate heartbeats, even with longer pathway stimulation or without prior 3D aggregate formation. However, simultaneous stimulation with both BMP and WNT yielded more consistent results in dissociation experiments and, on average, led to higher differentiation efficiency.

[0044] Figure 6A and Figure 6B This demonstrates the independence of cardiac differentiation from basal culture medium. Figure 6AThe cardiac induction protocol using IMDM as the basal medium is illustrated schematically. B: BMP pathway stimulation; W: classical WNT pathway stimulation; Wi: classical WNT signaling inhibition. ITS: insulin / transferrin / selenium supplement; AscP: L-ascorbic acid 2-phosphate; HSA: human serum albumin; Gln: L-glutamine. Figure 6B The flow cytometry analysis of cardiac differentiation on day 9 using IMDM as the basal medium and cTnT as a proof-of-concept experiment is shown.

[0045] Figure 7 This demonstrates the importance of WNT inhibition for cardiac induction after signaling pathway activation. Flow cytometry analysis of cardiac troponin T (cTnT) was performed 9 days after differentiation with different amounts of C-59 (a WNT inhibitor). Results indicated a wide working concentration range and no significant cytotoxicity (morphological observation). Note that the absence of WNT inhibition resulted in a low percentage of cardiomyocytes (top panel). The treatment duration of WNT inhibition was flexible and could be extended to at least day 7 (based on representative cTnT flow cytometry data) (bottom panel).

[0046] Figure 8 The importance of the additives L-ascorbic acid and albumin (HSA) was demonstrated. Gene expression analysis was performed after cardiac induction with the additives supplemented during the indication phase. The synergistic effect of ASC and HSA was shown: neither compound alone could support robust cardiac induction (in one experiment under semi-optimized conditions of the protocol).

[0047] Figure 9A The results of the RNA-Seq analysis are shown. The RNA-seq analysis revealed that, for important cardiac genes, the markers and annotations of cardiac differentiation clusters were much richer than those of other differentiated cell types.

[0048] Figure 9B RT-qPCR analysis was presented, confirming the expected time patterns (n=3) of early / immature (pink), pan / stable (gray), and mature markers of iPSC-CMs under 3D conditions. Note the exchange of myosin light and heavy chain encoding genes via alternative splicing variants.

[0049] Figure 9C Immunostaining of iPSC-CMs under adherent conditions is shown. Immunostaining of mature iPSC-CMs under adherent conditions reveals distinct sarcomere structures. Detailed Implementation

[0050] The essence of this invention lies in its innovative approach of partially replacing, rather than completely replacing, the culture medium when switching PSCs from WNT-activating to WNT-inhibiting conditions for cardiomyocyte differentiation. This meticulous method eliminates the need for conventional full-volume medium replacement, significantly improving the consistency and efficiency of cardiomyocyte production by maintaining limited exposure to WNT activators while simultaneously initiating WNT inhibition. Crucially, this method minimizes batch-to-batch variability, establishing a more reliable and effective protocol for cardiomyocyte generation, thereby advancing the field of regenerative medicine and its therapeutic applications.

[0051] Before describing the compositions and methods of the present invention, it should be understood that the invention is not limited to the specific compositions, methods, and experimental conditions described, as these compositions, methods, and conditions may vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting, as the scope of the invention will be limited to the appended claims.

[0052] The singular forms “a,” “an,” and “the” used in this specification and the appended claims include plural references unless the context clearly indicates otherwise. Thus, for example, a reference to “the method” includes one or more methods and / or steps of the type described herein, as will be apparent to those skilled in the art upon reading this disclosure, and so on.

[0053] All publications, patents and patent applications mentioned in this specification are incorporated herein by reference to the same extent that each individual publication, patent or patent application is specifically and individually indicated to be incorporated by reference.

[0054] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. While the invention may be practiced or tested using any methods and materials similar to or equivalent to those described herein, it should be understood that modifications and variations are included within the spirit and scope of this disclosure. Preferred methods and materials will now be described.

[0055] In one aspect, the present invention provides a method for inducing cardiomyocyte differentiation from pluripotent stem cells (PSCs), comprising: a) contacting PSCs in a culture medium for one or several days, wherein the culture medium contains a WNT signaling pathway activator and: (i) a bone morphogenetic protein (BMP) signaling pathway activator; (ii) optionally an FGF / ERK signaling pathway activator; and (iii) optionally a TGF-β signaling pathway activator; and b) partially replacing the culture medium in a) with a culture medium containing a WNT signaling pathway inhibitor, and further culturing for one or several days, thereby inducing PSCs to differentiate into cardiomyocytes.

[0056] The methods described in this article offer valuable applications for the economical and reproducible generation of human cardiomyocyte progenitors or cardiomyocytes. Specifically, these methods promote the generation of cardiomyocyte progenitors or cardiomyocytes by partially replacing the culture medium during the transition from WNT activation to inhibition conditions, potentially advancing their application in regenerative therapy.

[0057] The term "contact" refers to the culture of cells with one or more relevant reagents added to a defined basal or supplemental culture medium. That is, cells are cultured in their standard basal or supplemental medium with the desired concentration of one or more relevant reagents added. For example, cells may be cultured with BMP signaling pathway activators, WNT signaling pathway activators and / or inhibitors, FGF / ERK signaling pathway activators, and TGF-β signaling pathway activators. As described herein, cells cultured with Rho-associated kinase (ROCK) inhibitors are referred to as ROCK inhibitor-cultured cells.

[0058] As used herein, "signaling pathway activator" refers to any molecule capable of activating, enhancing, or inducing a related signaling pathway. A signaling pathway is a series of chemical reactions in which a group of molecules in a cell work together to control cellular functions, such as cell differentiation. When a molecule (such as a hormone or growth factor) binds to a specific protein receptor on or within a cell, the cell receives a signal from its environment. Once the first molecule in the pathway receives the signal, it activates another molecule. This process repeats throughout the signaling pathway until the last molecule is activated and cellular function is performed. Aberrant activation or inhibition of a signaling pathway can lead to disease, or, in the case of pluripotent cells, to an alteration of pluripotency and thus differentiation. The term "molecule" includes (as a non-limiting example): small molecules (including small molecules with poor cell permeability), lipids, nucleosides, nucleotides, nucleic acids, polynucleotides, oligonucleotides, antibodies, toxins, negatively charged polymers, and other polymers such as proteins, peptides, hormones, carbohydrates, or polyamines. Non-limiting examples of polynucleotides include short interfering nucleic acids (siNA), antisense nucleic acids, enzymatic nucleic acid molecules, 2',5'-oligoadenic acid, triple-stranded oligonucleotides, aptamers, and decoys. Bioactive molecules include antibodies (e.g., monoclonal antibodies, chimeric antibodies, humanized antibodies, etc.), cholesterol, hormones, antiviral agents, peptides, proteins, chemotherapeutic agents, small molecules, vitamins, cofactors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triple-stranded oligonucleotides, 2,5-A chimeras, allosteric enzymes, aptamers, decoys, and analogues thereof, as well as small nucleic acid molecules such as short interfering nucleic acids (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), microRNA antagomir, and short hairpin RNA (shRNA) molecules.

[0059] In some embodiments, this disclosure relates to obtaining cardiomyocytes by exposing pluripotent stem cells (PSCs) to a cardiomyocyte induction composition. As detailed herein, the cardiomyocyte induction composition may vary and generally includes effective amounts of one or more of the following: BMP signaling pathway activators, WNT signaling pathway activators and / or inhibitors, FGF / ERK signaling pathway activators, and TGF-β signaling pathway activators. In some embodiments, the inducing agent that can be used for cardiomyocyte induction may include an activator or inhibitor of the BMP signaling pathway. Activators and inhibitors of the BMP signaling pathway include small molecule activators, small molecule inhibitors, peptide activators, peptide inhibitors, antibodies, nucleic acid activators, nucleic acid inhibitors, etc., that activate or inhibit at least one component of the BMP signaling pathway, thereby causing corresponding activation or inhibition of cellular BMP signaling.

[0060] The transforming growth factor β (TGF-β) superfamily includes TGF-β protein, bone morphogenetic proteins (BMPs), growth differentiation factors (GDFs), glial cell-derived neurotrophic factors (GDNFs), activins, inhibins, nodal, lefty, and Müllerian duct inhibitors (MIS). Bone morphogenetic proteins (BMPs) are a group of growth factors, also known as cytokines and metabolites. Initially discovered for their ability to induce bone and cartilage formation, BMPs are now considered to constitute a key set of morphogenetic signaling molecules that coordinate the structure of tissues throughout the body. The crucial physiological role of BMP signaling is highlighted by the numerous roles of dysregulated BMP signaling in pathological processes.

[0061] BMPs interact with specific receptors on the cell surface, known as bone morphogenetic protein receptors (BMPRs). Signal transduction via BMPRs leads to the mobilization of SMAD family protein members. Signaling pathways involving BMPs, BMPRs, and SMADs are important in the development of the heart, central nervous system, and cartilage, as well as in postnatal skeletal development. They play a crucial role in embryonic patterning and early skeletal formation during embryonic development. Therefore, disruption of BMP signaling can affect the body axis pattern of the developing embryo. For example, BMP4 and its inhibitors, noggin and chordin, help regulate embryonic polarity (i.e., anterior-posterior pattern). Specifically, BMP4 and its inhibitors play important roles in neurogenesis and neural plate development. BMP4 signaling enables ectoderm cells to develop into skin cells, but inhibitors secreted by the underlying mesoderm block the action of BMP4, allowing the ectoderm to continue its normal neural cell development process.

[0062] Activators of the BMP pathway include (as a non-limiting example): BMP family ligands, such as BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8, BMP9, BMP8b, BMP10, BMP11, and BMP15; alantolactone; FK506; isoliquiritigenin; and 4'-hydroxychalcone. In some embodiments, activation of the BMP pathway can be achieved by inhibiting BMP pathway inhibitors, said inhibition including (as a non-limiting example) using an inhibitory nucleic acid targeting a BMP pathway inhibitor, or an antibody or small molecule targeting a BMP pathway inhibitor. In some embodiments, the BMP pathway activator includes BMP4.

[0063] The WNT signaling pathway is a group of signal transduction pathways that begin by transmitting signals to intracellular proteins via cell surface receptors. The WNT signaling pathway utilizes either neighboring cell-to-cell communication (paracrine) or intracellular communication (autocrine). Three WNT signaling pathways have been characterized: the classical WNT pathway, the non-classical planar cell polarity pathway, and the non-classical WNT / calcium pathway. All three pathways are activated by the binding of WNT protein ligands to Frizzled family receptors, which transmit biological signals to disheveled proteins within the cell. The classical WNT pathway leads to the regulation of gene transcription and is thought to be partially negatively regulated by the SPATS1 gene. The non-classical planar cell polarity pathway regulates the cytoskeleton, which is responsible for cell shape. The non-classical WNT / calcium pathway regulates intracellular calcium. WNT signaling was first identified for its role in oncogenesis and subsequently for its function in embryonic development. Embryonic processes controlled by WNT signaling include body axis patterning, cell fate determination, cell proliferation, and cell migration. These processes are essential for the proper formation of important tissues, including bone, heart, and muscle. The role of WNT signaling in embryonic development was discovered in abnormal fruit fly embryos resulting from gene mutations in WNT pathway proteins. Subsequent studies found that genes leading to these abnormalities also affect breast cancer development in mice. WNT signaling also controls tissue regeneration in adult bone marrow, skin, and intestines.

[0064] In some embodiments, the inducers that can be used for cardiomyocyte induction may include activators or inhibitors of the WNT signaling pathway. Activators and inhibitors of the WNT signaling pathway include (as non-limiting examples): small molecule activators, small molecule inhibitors, peptide activators, peptide inhibitors, antibodies, nucleic acid activators, nucleic acid inhibitors, etc., that activate or inhibit at least one component of the WNT signaling pathway to cause corresponding activation or inhibition of cellular WNT signaling.

[0065] Activators of the WNT signaling pathway include (as a non-limiting example): CHIR99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarboxylonite); WNT family ligands include (as a non-limiting example): Wnt-1, Wnt-2, Wnt-2b, Wnt-3a, Wnt-4, Wnt-5a, Wnt-5b, Wnt-6, Wnt-7a, Wnt-7a / b, Wnt-7b, Wnt-8a, Wnt-8b, Wnt-9a, Wnt -9b, Wnt-10a, Wnt-10b, Wnt-11, and Wnt-16b; RSPO co-agonists (e.g., RSPO2); lithium chloride; TDZD8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione); BIO-acetyl oxime ((2'Z,3'E)-6-bromoindorubin-3'-acetaldehyde oxime); A1070722 (1-(7-methoxyquinoline-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea); HLY78 (4-ethyl-5,6-dihydro-5-methyl-[1,3]dioxacyclopenten[4,5-j]phenanthridine); CID 11210285 hydrochloride (2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine hydrochloride); WAY-316606; (hetero)arylpyrimidine; IQ1; QS11; SB-216763; DCA; etc. In some embodiments, activation of the WNT signaling pathway can be achieved by inhibiting WNT signaling pathway inhibitors, including (as a non-limiting example) using antisense nucleic acids targeting WNT signaling pathway inhibitors, or antibodies or small molecules targeting WNT signaling pathway inhibitors.

[0066] In some embodiments, the WNT signaling pathway activator includes CHIR99021. In some embodiments, the WNT signaling pathway activator includes a derivative of CHIR99021. In some embodiments, one or more WNT signaling pathway activators are used.

[0067] Inhibitors of the WNT signaling pathway include (as non-limiting examples): C-59 (4-(2-methyl-4-pyridyl)-N-[4-(3-pyridyl)phenyl]phenylacetamide), DKK1, IWP2 (N-(6-methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]acetamide), Ant1.4Br, Ant1.4 CI, Niclosamide, apicularen, bafilomycin, XAV939 (3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiaro[4,3-d]pyrimidin-4-one), IWR1 (4-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methylbridge-2H-isoindol-2-yl)-N-8-quinolinyl-benzene) Formamide), NSC668036 (N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-(2S)-2-hydroxy-3-methylbutyryl-L-alanine-(1S)-1-carboxy-2-methylpropyl ester hydrate), 2,4-diamino-quinazoline, quercetin, ICG-001 ((6S,9aS)-hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthylmethyl) -4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-formamide), PKF115-584, BML-284 (2-amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3-methoxyphenyl)pyrimidine), FH-535, iCRT-14, JW-55, JW-67, antibodies against WNTs and WNT receptors, WNT inhibitory nucleic acids, etc.

[0068] In some embodiments, the WNT signaling pathway inhibitor is selected from IWP2, IWR1, or C-59. In some embodiments, the WNT signaling pathway inhibitor includes derivatives of IWP2, IWR1, or C-59. In some embodiments, one or more WNT signaling pathway inhibitors are used.

[0069] In some embodiments, the inducers that can be used to induce cardiomyocytes may include activators or inhibitors of the FGF signaling pathway. In some cases, the activators or inhibitors of the FGF signaling pathway may also include activators or inhibitors of related signaling pathways, with non-limiting examples including the MAPK / ERK signaling pathway. Activators and inhibitors of the FGF signaling pathway include small molecule activators, small molecule inhibitors, peptide activators, peptide inhibitors, antibodies, nucleic acid activators, nucleic acid inhibitors, etc., which activate or inhibit at least one component of the FGF signaling pathway, thereby producing corresponding activation or inhibition in cellular FGF signaling.

[0070] Non-limiting embodiments of activators of the FGF signaling pathway and / or the MAPK / ERK signaling pathway include: FGF family ligands, including, but not limited to, FGF1, FGF2, FGF-3, FGF-4, FGF-5, FGF-6, KGF / FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-15, FGF-16, FGF-17, FGF-19, FGF-20, FGF-21, FGF-22, and FGF-23; SUN 11602 (4-[[4-[[2-[(4-amino-2,3,5,6-tetramethylphenyl)amino]acetyl]methylamino]-1-piperidinyl]methoxybenzamide); tert-butylhydroquinone; U-46619; C2 ceramide; lactose ceramide; angiotensin II; baicalin; etc. In some embodiments, activation of the FGF signaling pathway and / or MAPK / ERK signaling pathway can be achieved by inhibiting FGF signaling pathway inhibitors and / or MAPK / ERK signaling pathway inhibitors, and non-limiting embodiments thereof include using inhibitory nucleic acids that target FGF signaling pathway and / or MAPK / ERK signaling pathway inhibitors, or antibodies or small molecules that target FGF signaling pathway inhibitors and / or MAPK / ERK signaling pathway inhibitors.

[0071] In some embodiments, the inducer that can be used to induce cardiomyocytes may include an activator or inhibitor of the TGF-β signaling pathway. Non-limiting examples of activators and inhibitors of the TGF-β signaling pathway include small molecule activators, small molecule inhibitors, peptide activators, peptide inhibitors, antibodies, nucleic acid activators, nucleic acid inhibitors, etc., which activate or inhibit at least one component of the TGF-β signaling pathway, thereby producing corresponding activation or inhibition in cellular TGF-β signaling.

[0072] Non-limiting embodiments of activators of the TGF-β signaling pathway include: TGF-β family ligands (e.g., other activators of the TGF-β protein and TGF-β receptor) and portions thereof, activin A, TGF-β1, TGF-β2, TGF-β3, IDE1 / 2 (IDE1 [1-[2-[(2-carboxyphenyl)methylene]hydrazino]heptanoic acid], IDE2 [pimecrolic acid-1-(2-cyclopentylhydrazino)]), Nodal, etc. In some embodiments, activation of the TGF-β signaling pathway can be achieved by inhibiting a TGF-β signaling pathway inhibitor, non-limiting embodiments of which include using an inhibitory nucleic acid targeting a TGF-β signaling pathway inhibitor, or an antibody or small molecule targeting a TGF-β signaling pathway inhibitor. In some embodiments, the TGF-β signaling pathway activator comprises activin A. In some embodiments, the TGF-β signaling pathway activator comprises a derivative of activin A. In some embodiments, one or more TGF-β signaling pathway activators are used.

[0073] In some embodiments, the chemical culture conditions of the methods described herein include a mixture of reagents, said mixture comprising a BMP signaling pathway activator (which may include any BMP signaling pathway activator listed in this disclosure), a WNT signaling pathway activator and / or inhibitor (which may include any WNT signaling pathway activator or WNT signaling pathway inhibitor listed in this disclosure), an FGF / ERK signaling pathway activator (which may include any FGF / ERK signaling pathway activator listed in this disclosure), and a TGF-β signaling pathway activator (which may include any TGF-β signaling pathway activator listed in this disclosure).

[0074] For example, the pharmaceutical mixture comprises a BMP signaling pathway activator and a WNT signaling pathway activator and / or inhibitor. In another embodiment, the pharmaceutical mixture comprises, individually, a BMP signaling pathway activator, a WNT signaling pathway activator and / or inhibitor, or an FGF / ERK signaling pathway activator. In yet another embodiment, the pharmaceutical mixture comprises a WNT signaling pathway activator and / or inhibitor, an FGF / ERK signaling pathway activator, or a TGF-β signaling pathway activator.

[0075] In some embodiments, the PSCs are grown for approximately one day, 1 to 2 days, 1 to 3 days, 1 to 4 days, 1 to 5 days, 1 to 6 days, 1 to 7 days, 1 to 8 days, or more than 8 days, or for any length of time within any two of the above or described herein, in the presence of WNT and BMP signaling pathway activators. For example, the cells are grown for approximately 1, 2, 3, 4, 5, 6, 7, 8 days, or more, or for any length of time within any two of the above or described herein, in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSCs are grown for at least 2 days in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSCs are grown for 1 day in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSCs are grown for 2 days in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSC is grown for 3 days in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSC is grown for 4 days in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSC is grown for 5 days in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSC is grown for 6 days in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSC is grown for 7 days in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSC is grown for 8 days in the presence of WNT and BMP signaling pathway activators. In some embodiments, the PSC is grown for more than 8 days in the presence of WNT and BMP signaling pathway activators.

[0076] In some embodiments, after initial culture in the presence of WNT and BMP signaling pathway activators, the PSCs are grown for approximately one day, 1 to 2 days, 1 to 3 days, 1 to 4 days, 1 to 5 days, 1 to 6 days, 1 to 7 days, 1 to 8 days, or more than 8 days, or for any length of time within any two of the above or described herein number of days, in the presence of FGF / ERK and / or TGF-β signaling pathway activators. For example, after initial culture, the cells are grown for approximately 1, 2, 3, 4, 5, 6, 7, 8 days, or more, or for any length of time within any two of the above or described herein number of days, in the presence of FGF / ERK and / or TGF-β signaling pathway activators. In some embodiments, the PSCs are grown for 1 day in the presence of FGF / ERK and / or TGF-β signaling pathway activators. In some embodiments, the PSC is grown for 2 days in the presence of an FGF / ERK signaling pathway activator and / or a TGF-β signaling pathway activator. In some embodiments, the PSC is grown for 3 days in the presence of an FGF / ERK signaling pathway activator and / or a TGF-β signaling pathway activator. In some embodiments, the PSC is grown for 4 days in the presence of an FGF / ERK signaling pathway activator and / or a TGF-β signaling pathway activator. In some embodiments, the PSC is grown for 5 days in the presence of an FGF / ERK signaling pathway activator and / or a TGF-β signaling pathway activator. In some embodiments, the PSC is grown for 6 days in the presence of an FGF / ERK signaling pathway activator and / or a TGF-β signaling pathway activator. In some embodiments, the PSC is grown for 7 days in the presence of an FGF / ERK signaling pathway activator and / or a TGF-β signaling pathway activator. In some embodiments, the PSC is grown for 8 days in the presence of an FGF / ERK signaling pathway activator and / or a TGF-β signaling pathway activator. In some embodiments, the PSC is grown for more than 8 days in the presence of FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators.

[0077] In some embodiments, after initial culture in the presence of WNT and BMP signaling pathway activators, the PSCs are grown for approximately one day, 1 to 2 days, 1 to 3 days, 1 to 4 days, 1 to 5 days, 1 to 6 days, 1 to 7 days, 1 to 8 days, or more than 8 days, or for any length of time within any two of the stated number of days, in the presence of FGF / ERK and / or TGF-β, WNT, and BMP signaling pathway activators. For example, after initial culture, the cells are grown for approximately 1, 2, 3, 4, 5, 6, 7, 8 days, or more, or for any length of time within any two of the stated number of days, in the presence of FGF / ERK and / or TGF-β, WNT, and BMP signaling pathway activators. In some embodiments, the PSC is grown for 1 day in the presence of FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators, WNT signaling activators, and BMP signaling activators. In some embodiments, the PSC is grown for 2 days in the presence of FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators, WNT signaling activators, and BMP signaling activators. In some embodiments, the PSC is grown for 3 days in the presence of FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators, WNT signaling activators, and BMP signaling activators. In some embodiments, the PSC is grown for 4 days in the presence of FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators, WNT signaling activators, and BMP signaling activators. In some embodiments, the PSC is grown for 5 days in the presence of FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators, WNT signaling activators, and BMP signaling activators. In some embodiments, the PSC is grown for 6 days in the presence of FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators, WNT signaling activators, and BMP signaling activators. In some embodiments, the PSC is grown for 7 days in the presence of FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators, WNT signaling activators, and BMP signaling activators. In some embodiments, the PSC is grown for more than 8 days in the presence of FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators, WNT signaling activators, and BMP signaling activators.

[0078] In some embodiments, the PSC culture is contacted with WNT and BMP signaling pathway activators for about 3 days, and then with FGF / ERK and / or TGF-β signaling pathway activators for another 4 days.

[0079] In some embodiments, contacting the PSC culture includes one or more agents selected from the group consisting of about 0.1-10 µM of a WNT signaling pathway activator, including any WNT signaling pathway activator disclosed herein. In some embodiments, contacting the PSC culture includes about 5-100 ng / ml of any BMP signaling pathway activator disclosed herein. In some embodiments, contacting the PSC culture includes about 2.5 ng / ml to 20 ng / ml of an FGF / ERK signaling pathway activator disclosed herein. In some embodiments, contacting the PSC culture includes about 2.5 ng / ml to 20 ng / ml of a TGF-β signaling pathway activator disclosed herein. In some embodiments, contacting the PSC culture includes one or more agents selected from the following: about 0.1-10 µM of a WNT signaling pathway activator, about 5-100 ng / ml of a BMP signaling pathway activator, about 2.5 ng / ml to 20 ng / ml of an FGF / ERK signaling pathway activator, and about 2.5 ng / ml to 20 ng / ml of a TGF-β signaling pathway activator. In some embodiments, contacting the PSC culture includes one or more agents selected from the following: about 0.5 µM or about 1 µM of a WNT signaling pathway activator, about 5 ng / ml of a BMP signaling pathway activator, about 5 ng / ml or about 7.5 ng / ml of an FGF / ERK signaling pathway activator, and about 5 ng / ml or about 7.5 ng / ml of a TGF-β signaling pathway activator.

[0080] The WNT signaling pathway activator is added to the PSC culture at a concentration ranging from about 0.1 µM to 10 µM. For example, the PSCs are grown in a medium containing about 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10.5 µM or more of the WNT signaling pathway activator (including any WNT signaling pathway activator disclosed herein). In some embodiments, the WNT signaling pathway activator is added to the PSC culture at concentrations ranging from 0.05 to 0.06 µM, 0.06 to 0.07 µM, 0.07 to 0.08 µM, 0.08 to 0.09 µM, 0.09 to 0.1 µM, 0.1 µM to 0.5 µM, 0.5 µM to 1.0 µM, 1.0 to 2.0 µM, 2.0 to 3.0 µM, 3.0 to 4.0 µM, 4.0 to 5.0 µM, 5.0 to 6.0 µM, 6.0 to 7.0 µM, 7.0 to 8.0 µM, 8.0 to 9.0 µM, 9.0 to 10 µM, and 10.0 to 10.5 µM, or within any two of the concentrations described above or herein. In some embodiments, the mixture comprises about 1 µM of the WNT signaling pathway activator. In some embodiments, the mixture comprises about 0.5 µM of a WNT signaling pathway activator. In some embodiments, the mixture comprises about 0.5 µM or 1 µM of CHIR99021.

[0081] The BMP signaling pathway activator is added to the PSC culture at a concentration ranging from about 1 ng / ml to about 10 ng / ml. For example, the PSCs are grown in a medium comprising about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10.5 ng / ml or more of a BMP signaling pathway activator (including any BMP signaling pathway activator disclosed herein). In some embodiments, the concentration of the BMP pathway activator is between about 1 ng / ml and 10 ng / ml. In some embodiments, the concentration of the BMP pathway activator is in the range of 0.5 to 0.6 ng / ml, 0.6 to 0.7 ng / ml, 0.7 to 0.8 ng / ml, 0.8 to 0.9 ng / ml, 0.9 to 1 ng / ml, 1 to 2 ng / ml, 2 to 3 ng / ml, 3 to 4 ng / ml, 4 to 5 ng / ml, 5 to 6 ng / ml, 6 to 7 ng / ml, 7 to 8 ng / ml, 8 to 9 ng / ml, 9 to 10 ng / ml, 10 to 10.5 ng / ml, or within the range of any two of the above or described herein. In some embodiments, the mixture comprises about 5 ng / ml of BMP4. In some embodiments, the mixture comprises about 7.5 ng / ml of BMP4.

[0082] As further described in the examples, BMP4 can be prepared by resuspending it in various solutions. For example, dried BMP4 can be resuspended in PBS / 0.01% HSA or in citric acid (as recommended by the manufacturer). PBS / 0.01% HSA may reduce the biological activity of BMP4 compared to its activity when prepared in citric acid. Those skilled in the art will readily recognize that BMP4 exhibits greater biological activity when resuspended in citric acid, thus allowing for a significant reduction in concentrations of 1-10 ng / ml.

[0083] FGF / ERK signaling pathway activator was added to PSC cultures at concentrations ranging from about 2.5 ng / ml to about 20 ng / ml. For example, PSCs are grown in media containing approximately 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25 ng / ml or more of an FGF / ERK signaling pathway activator, including any FGF / ERK signaling pathway activator disclosed herein.In some embodiments, the concentration range of the FGF / ERK signaling pathway activator is 0.25 to 0.5 ng / ml, 0.5 to 0.75 ng / ml, 0.75 to 1 ng / ml, 1 to 1.5 ng / ml, 1.5 to 2 ng / ml, 2 to 2.5 ng / ml, 2.5 to 3 ng / ml, 3 to 3.5 ng / ml, 3.5 to 4 ng / ml, 4 to 4.5 ng / ml, 4.5 to 5 ng / ml, 5 to 5.5 ng / ml, 5.5 to 6 ng / ml, 6 to 6.5 ng / ml, 6.5 to 7 ng / ml, 7 to 7.5 ng / ml, 7.5 to 8 ng / ml, 8 to 8.5 ng / ml, 8.5 to 9 ng / ml, 9 to 9.5 ng / ml, 9.5 to 10 ng / ml, and 10 to 10.5 ng / ml. ng / ml, 10.5 to 11 ng / ml, 11 to 11.5 ng / ml, 11.5 to 12 ng / ml, 12 to 12.5 ng / ml, 12.5 to 13 ng / ml, 13 to 13.5 ng / ml, 13.5 to 14 ng / ml, 14 to 14.5 ng / ml, 14.5 to 15 ng / ml, 15 to 15.5 ng / ml, 15.5 to 16 ng / ml, 16 to 16.5 ng / ml, 16.5 to 17 ng / ml, 17 to 17.5 ng / ml, 17.5 to 18 ng / ml, 18 to 18.5 ng / ml, 18.5 to 19 ng / ml, 19 to 19.5 ng / ml, 19.5 to 20 ng / ml, 20 to 20.5 The concentrations are 20.5 to 21 ng / ml, 21 to 21.5 ng / ml, 21.5 to 22 ng / ml, 22 to 22.5 ng / ml, 22.5 to 23 ng / ml, 23 to 3.5 ng / ml, 23.5 to 24 ng / ml, 24 to 24.5 ng / ml, 24.5 to 25 ng / ml, or ranges between any two concentrations mentioned above or herein. In some embodiments, the mixture comprises about 5 ng / ml of an FGF / ERK signaling pathway activator. In some embodiments, the mixture comprises about 7.5 ng / ml of an FGF / ERK signaling pathway activator. In some embodiments, the mixture comprises about 5 or about 7.5 ng / ml of FGF2.

[0084] TGF-β signaling pathway activator was added to PSC cultures at concentrations ranging from about 2.5 ng / ml to about 20 ng / ml. For example, PSCs are grown in a medium containing about 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25 ng / ml or more of a TGF-β signaling pathway activator, including any TGF-β signaling pathway activator disclosed herein.In some embodiments, the concentration range of the TGF-β signaling pathway activator is 0.25 to 0.5 ng / ml, 0.5 to 0.75 ng / ml, 0.75 to 1 ng / ml, 1 to 1.5 ng / ml, 1.5 to 2 ng / ml, 2 to 2.5 ng / ml, 2.5 to 3 ng / ml, 3 to 3.5 ng / ml, 3.5 to 4 ng / ml, 4 to 4.5 ng / ml, 4.5 to 5 ng / ml, 5 to 5.5 ng / ml, 5.5 to 6 ng / ml, 6 to 6.5 ng / ml, 6.5 to 7 ng / ml, 7 to 7.5 ng / ml, 7.5 to 8 ng / ml, 8 to 8.5 ng / ml, 8.5 to 9 ng / ml, 9 to 9.5 ng / ml, 9.5 to 10 ng / ml, and 10 to 10.5 ng / ml. ng / ml, 10.5 to 11 ng / ml, 11 to 11.5 ng / ml, 11.5 to 12 ng / ml, 12 to 12.5 ng / ml, 12.5 to 13 ng / ml, 13 to 13.5 ng / ml, 13.5 to 14 ng / ml, 14 to 14.5 ng / ml, 14.5 to 15 ng / ml, 15 to 15.5 ng / ml, 15.5 to 16 ng / ml, 16 to 16.5 ng / ml, 16.5 to 17 ng / ml, 17 to 17.5 ng / ml, 17.5 to 18 ng / ml, 18 to 18.5 ng / ml, 18.5 to 19 ng / ml, 19 to 19.5 ng / ml, 19.5 to 20 ng / ml, 20 to 20.5 The concentrations are 20.5 to 21 ng / ml, 21 to 21.5 ng / ml, 21.5 to 22 ng / ml, 22 to 22.5 ng / ml, 22.5 to 23 ng / ml, 23 to 23.5 ng / ml, 23.5 to 24 ng / ml, 24 to 24.5 ng / ml, 24.5 to 25 ng / ml, or ranges between any two concentrations mentioned above or herein. In some embodiments, the mixture comprises about 5 ng / ml of a TGF-β signaling pathway activator. In some embodiments, the mixture comprises about 7.5 ng / ml of a TGF-β signaling pathway activator. In some embodiments, the mixture comprises about 5 or about 7.5 ng / ml of activator A.

[0085] In some implementations, the PSC culture is contacted with approximately 0.5 µM CHIR99021 and approximately 5 ng / ml BMP4.

[0086] In some implementations, the PSC culture is exposed to approximately 0.5 µM CHIR99021, approximately 5 ng / ml BMP4, and approximately 7.5 ng / ml FGF2.

[0087] In some embodiments, the PSC culture is exposed to approximately 0.5 µM CHIR99021, approximately 5 ng / ml BMP4, and approximately 7.5 ng / ml activin A.

[0088] In some embodiments, the PSC culture is exposed to approximately 0.5 µM CHIR99021, approximately 5 ng / ml BMP4, approximately 7.5 ng / ml FGF2, and approximately 7.5 ng / ml activin A.

[0089] In some implementations, the PSC culture is exposed to approximately 0.5 µM CHIR99021, approximately 5 ng / ml BMP4, and approximately 5 ng / ml FGF2.

[0090] In some embodiments, the PSC culture is exposed to approximately 0.5 µM CHIR99021, approximately 5 ng / ml BMP4, and approximately 5 ng / ml activin A.

[0091] In some embodiments, the PSC culture is exposed to approximately 0.5 µM CHIR99021, approximately 5 ng / ml BMP4, approximately 5 ng / ml FGF2, and approximately 5 ng / ml activin A.

[0092] In some implementations, the PSC culture is contacted with approximately 1 µM CHIR99021.

[0093] In some implementations, the PSC culture is exposed to approximately 1 µM CHIR99021 and approximately 5 ng / ml BMP4.

[0094] In some implementations, the PSC culture is exposed to approximately 1 µM CHIR99021, approximately 5 ng / ml BMP4, and approximately 7.5 ng / ml FGF2.

[0095] In some embodiments, the PSC culture is exposed to approximately 1 µM CHIR99021, approximately 5 ng / ml BMP4, approximately 7.5 ng / ml FGF2, and approximately 7.5 ng / ml activin A.

[0096] In some implementations, the PSC culture is exposed to approximately 1 µM CHIR99021, approximately 5 ng / ml BMP4, and approximately 5 ng / ml FGF2.

[0097] In some embodiments, the PSC culture is exposed to approximately 1 µM CHIR99021, approximately 5 ng / ml BMP4, approximately 5 ng / ml FGF2, and approximately 5 ng / ml activin A.

[0098] In some implementations, PSC cultures were contacted with WNT signaling pathway activator and BMP signaling pathway activator for approximately 2 to 5 days.

[0099] In some implementations, PSC cultures were contacted with WNT signaling pathway activator and BMP signaling pathway activator for approximately 3 to 5 days.

[0100] In some implementations, PSC cultures were contacted with WNT signaling pathway activator and BMP signaling pathway activator for approximately 4 to 5 days.

[0101] In some implementations, PSC cultures were contacted with WNT signaling pathway activators and BMP signaling pathway activators for approximately 2, 3, 4, or 5 days, or for any period between any two of the listed days.

[0102] In some implementations, the PSC is subsequently exposed to FGF / ERK signaling pathway activator and / or TGF-β signaling pathway activator for approximately 2 to 5 days.

[0103] In some implementations, the PSC is subsequently exposed to FGF / ERK signaling pathway activator and / or TGF-β signaling pathway activator for approximately 3 to 5 days.

[0104] In some implementations, the PSC is subsequently exposed to FGF / ERK signaling pathway activator and / or TGF-β signaling pathway activator for approximately 4 to 5 days.

[0105] In some implementations, the PSC is subsequently exposed to FGF / ERK signaling pathway activators and / or TGF-β signaling pathway activators for approximately 2, 3, 4, or 5 days, or for any period between any two of the listed days.

[0106] The culture medium exposed to PSCs is partially exchanged with a culture medium containing inhibitors of the WNT signaling pathway for one or more days.

[0107] In some embodiments, the culture medium contacting the PSCs is partially exchanged with a culture medium containing an inhibitor of the WNT signaling pathway at a volume ranging from about 5% to 90% for one or more days. In some embodiments, the volume of the exchanged culture medium is about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90% of the culture medium contacting the PSCs, or any percentage between any two of the percentages mentioned above or herein.

[0108] In some implementations, the volume of the exchanged medium is about 10%, 25%, 50% or 75% of the medium in contact with the PSC.

[0109] In some implementations, the volume of the culture medium exchanged is approximately 25% of the culture medium in contact with the PSC.

[0110] In some embodiments, the culture medium contacting the PSC is partially exchanged with a culture medium comprising at least about 0.1 µM of WNT signaling pathway inhibitors. For example, the culture medium is exchanged with a culture medium comprising about 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5 µM or more of WNT signaling pathway inhibitors, including any WNT signaling pathway inhibitors disclosed herein. In some embodiments, the WNT signaling pathway inhibitor is present at concentrations of 0.05 to 0.06 µM, 0.06 to 0.07 µM, 0.07 to 0.08 µM, 0.08 to 0.09 µM, 0.09 to 0.1 µM, 0.1 to 0.2 µM, 0.2 to 0.3 µM, 0.3 to 0.4 µM, 0.4 to 0.5 µM, 0.5 to 0.6 µM, 0.6 to 0.7 µM, 0.7 to 0.8 µM, 0.8 to 0.9 µM, 0.9 to 1 µM, 1.0 to 2.0 µM, 2.0 to 3.0 µM, 3.0 to 4.0 µM, 4.0 to 5.0 µM, 5.0 to 6.0 µM, 6.0 to 7.0 µM, 7.0 to 8.0 µM, 8.0 to 9.0 µM, 9.0 to 10 µM. Concentrations in the range of µM are added to PSC cultures, or concentrations between any two concentrations mentioned above or herein. In some embodiments, the culture medium includes about 2 µM of a WNT signaling pathway inhibitor. In some embodiments, the culture medium includes about 2 µM of a combination of WNT signaling pathway inhibitors, including C-59, IPW2, or IWR1. In some embodiments, the culture medium includes about 2 µM of C-59, 2 µM of IPW2, or 2 µM of IWR1.

[0111] In some embodiments, the culture medium exposed to PSCs is partially exchanged with a culture medium containing an inhibitor of the WNT signaling pathway for one or more days. For example, the culture medium exposed to PSCs is partially exchanged with a culture medium containing an inhibitor of the WNT signaling pathway for about 1, 2, 3, 4, 5, 6, 7, 8 or more days, or for any period of time between any two days listed above or herein. In some embodiments, the culture medium exposed to PSCs is partially exchanged with a culture medium containing an inhibitor of the WNT signaling pathway for about 2 to 5 days. In some embodiments, the culture medium exposed to PSCs is partially exchanged with a culture medium containing an inhibitor of the WNT signaling pathway for about 3 to 5 days. In some embodiments, the culture medium exposed to PSCs is partially exchanged with a culture medium containing an inhibitor of the WNT signaling pathway for about 4 to 5 days. In some embodiments, the culture medium exposed to PSCs is partially exchanged with a culture medium containing an inhibitor of the WNT signaling pathway for about 2, 3, 4 or 5 days. In some embodiments, the culture medium exposed to PSCs is partially exchanged with a culture medium containing an inhibitor of the WNT signaling pathway for more than 5 days.

[0112] In some embodiments, about 25% of the medium in contact with PSCs is exchanged with a medium containing 2 µM C-59 for about 2 to 5 days. In some embodiments, about 25% of the medium in contact with PSCs is exchanged with a medium containing 2 µM C-59 for about 3 to 5 days. In some embodiments, about 25% of the medium in contact with PSCs is exchanged with a medium containing 2 µM C-59 for about 4 to 5 days. In some embodiments, about 25% of the medium in contact with PSCs is exchanged with a medium containing 2 µM C-59 for about 2, 3, 4, or 5 days, or for any period between two days of any of the days listed above or herein.

[0113] In some embodiments, a culture medium supplement comprising or excluding vitamins, proteins, and amino acids is added to the culture medium. In some embodiments, the vitamin supplement is vitamin C as ascorbate, ascorbic acid, or any salt thereof or any derivative thereof. In some embodiments, the culture medium supplement includes vitamin C, which may be any vitamin C listed in this disclosure. In some embodiments, the culture medium supplement includes vitamin C or a salt thereof, which may include (as a non-limiting example) sodium, potassium, calcium, magnesium, lithium, and ammonium salts of vitamin C. In some embodiments, the vitamin C salt may be sodium ascorbate (also known as “mineral ascorbate”), calcium ascorbate, potassium ascorbate, magnesium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, or any combination thereof. In some embodiments, vitamin C may be vitamin C containing bioflavonoids, ascorbate and vitamin C metabolites, ascorbate palmitate, D-isoascorbic acid, or any combination thereof. In some embodiments, the culture medium includes ascorbate. In some embodiments, the ascorbate is 2-phosphate-L-ascorbate, its salts, or derivatives thereof. In some embodiments, the culture medium supplement includes 2-phosphate-L-ascorbate or its salts, which may include (as a non-limiting example) sodium, potassium, calcium, magnesium, lithium, and ammonium salts of 2-phosphate-L-ascorbic acid, such as trisodium 2-phosphate-L-ascorbate, sesquimagnesium L-ascorbic acid (also known as "magnesium 2-phosphate-L-ascorbate"), and 2-O-α-D-glucopyranosyl-L-ascorbic acid (also known as "ascorbate glucoside"). In some embodiments, vitamin C, ascorbate, 2-phosphate-L-ascorbate, ascorbic acid, and other forms of vitamin C are in salt form, which may include (as a non-limiting example) monosodium, disodium, trisodium, monopotassium, dipotassium, tripotassium, monoammonium, diammonium, or triammonium salts. In some embodiments, one or more derivatives of L-ascorbate 2-phosphate are optionally added to the culture medium. In some embodiments, one or more salts of ascorbate or L-ascorbate 2-phosphate are optionally added to the culture medium. In some embodiments, the protein supplement is albumin. In some embodiments, the albumin is HSA. In some embodiments, the amino acid supplement is glutamine. In some embodiments, ascorbate and / or albumin are added to the culture medium, and L-glutamine is optionally added. In some embodiments, about 250 µM of ascorbate 2-phosphate and / or about 5 mg / ml of albumin are added to the culture medium, and about 2 mM of L-glutamine is optionally added. In some embodiments, 250 µM of ascorbate 2-phosphate and / or 5 mg / ml of albumin are added to the culture medium, and 2 mM of L-glutamine is optionally added.

[0114] ROCK inhibitors include (as non-limiting examples) Y-27632, ripasudil, netarsudil, chroman 1, Y39983, Wf-536, SLx-2119, azabenzimidazole-aminofurazans, DE-104 olefins (Olefins), isoquinolines, indazoles, pyridinium derivatives, H-1152P, XD-4000, HMN-1152, and ROKα. 4-(1-Aminoalkyl)-N-(4-pyridyl)cyclohexanecarboxamide, rhostatin, BA-210, BA-207, BA-285, BA-1037, BA-215, Ki-23095, VAS-012, quinazoline, GSK-269962 and their salts, including Y-27632 dihydrochloride, H-1152 dihydrochloride, fasudil hydrochloride, SR-3677 dihydrochloride, glycyl-H-1152 dihydrochloride, SB-772077B dihydrochloride, TC-S-7001, RKI-1447 dihydrochloride and OXA-06 dihydrochloride. In some embodiments, the PSC culture is contacted with a culture medium containing a ROCK inhibitor, which can be any ROCK inhibitor shown in this disclosure, for at least one day. In some embodiments, the ROCK inhibitor is Y-27632. In some embodiments, the concentration of the ROCK inhibitor is in the range of about 1 µM to about 15 µM. In some embodiments, the concentration range of the ROCK inhibitor is 1.0 to 2.0 µM, 2.0 to 3.0 µM, 3.0 to 4.0 µM, 4.0 to 5.0 µM, 5.0 to 6.0 µM, 6.0 to 7.0 µM, 7.0 to 8.0 µM, 8.0 to 9.0 µM, 9.0 to 10 µM, 10 to 11 µM, 11 to 12 µM, 12 to 13 µM, 13 to 14 µM, 14 to 15 µM, or between any two concentrations mentioned above or herein. In some implementations, the concentration of Y-27632 is 10 µM.

[0115] In some embodiments, PSC cultures are contacted with a medium containing 10 µM Y-27632 for at least one day, then contacted with WNT and BMP signaling pathway activators for approximately 2 to 5 days, followed by contact with FGF / ERK and / or TGF-β signaling pathway activators for an additional 2 to 5 days, after which the medium is partially replaced with a medium containing a WNT signaling pathway inhibitor for one or more days. In some embodiments, PSC cultures are contacted with a medium containing 10 µM Y-27632 for at least one day, then the medium is replaced with a medium containing cells cultured with a ROCK inhibitor, and the cells are contacted with WNT and BMP signaling pathway activators for approximately 2 to 5 days, followed by contact with FGF / ERK and / or TGF-β signaling pathway activators for an additional 2 to 5 days, after which the medium is partially replaced with a medium containing a WNT signaling pathway inhibitor for one or more days. In some embodiments, the culture medium contacting cells cultured with the ROCK inhibitor is replaced with a medium containing approximately 0.5 µM CHIR99021, approximately 5 ng / ml BMP4, approximately 7.5 ng / ml FGF2, and approximately 7.5 ng / ml Activin A. In some embodiments, the culture medium contacting cells cultured with the ROCK inhibitor is replaced with a medium containing approximately 0.5 µM CHIR99021, approximately 5 ng / ml BMP4, approximately 5 ng / ml FGF2, and approximately 5 ng / ml Activin A. In some embodiments, the subsequently partially replaced culture medium containing a WNT signaling pathway inhibitor contains 2 µM C-59.

[0116] In some embodiments, the PSC culture is a cell-adherent layer. In some embodiments, the cell layer is grown in a two-dimensional culture system or on microcarriers.

[0117] In some embodiments, PSCs are cultured on a scaffold composed of microcarriers, which may be beads or particles. The beads can be microscopic or macroscopic and can be further sized to allow penetration into tissue or compacted to form a specific geometry. In some embodiments, the cell culture framework comprises particles that combine with cells to form a three-dimensional tissue. Cells attach to the particles and adhere to each other to form a three-dimensional tissue. Beads or microcarriers are generally considered to be two-dimensional systems or scaffolds.

[0118] As used herein, "microcarrier" refers to particles having a size ranging from nanometer to micrometer, wherein the particles can be of any shape or geometry and may be irregular, non-spherical, spherical, or ellipsoidal. The size of the microcarrier suitable for the purposes of this document can be any size appropriate for a particular application.

[0119] In some embodiments, the size of the microcarriers suitable for three-dimensional tissues can be an injection-applicable size. In some embodiments, the particle size range of the microcarriers is at least about 1 μm, at least about 10 μm, at least about 25 μm, at least about 50 μm, at least about 100 μm, at least about 200 μm, at least about 300 μm, at least about 400 μm, at least about 500 μm, at least about 600 μm, at least about 700 μm, at least about 800 μm, at least about 900 μm, at least about 1000 μm, or any size range between any two sizes mentioned above or herein.

[0120] In some embodiments, the microcarriers are made of biodegradable materials. In some embodiments, microcarriers comprising two or more layers of different biodegradable polymers may be used. In some embodiments, at least the outer layer has biodegradable properties for forming three-dimensional tissues in culture, while an inner second layer, having properties different from the first layer, is made to erode when applied to tissues or organs.

[0121] In some embodiments, the microcarrier is a porous microcarrier. A porous microcarrier is a microcarrier having gaps through which molecules can diffuse into or out of the microparticle. In other embodiments, the microcarrier is a non-porous microcarrier. Non-porous microparticles are microparticles of a specific size through which molecules do not diffuse into or out of the microparticle.

[0122] Microcarriers used in the composition are biocompatible and have low or no toxicity to cells. Microcarriers can comprise a variety of polymers, natural or synthetic, charged (i.e., anionic or cationic) or uncharged, biodegradable or non-biodegradable. The polymers can be homopolymers, random copolymers, block copolymers, graft copolymers, or branched polymers.

[0123] In some embodiments, the microcarriers comprise non-biodegradable microcarriers. Non-biodegradable microcapsules and microcarriers include (as a non-limiting example) those made of polysulfone, poly(acrylonitrile-co-vinyl chloride), ethylene-vinyl acetate, and hydroxyethyl methacrylate-methyl methacrylate copolymers. These can be used to provide tissue-enlarging properties or in embodiments where the microcarriers are eliminated from the body.

[0124] In some embodiments, the microcarriers comprise a biodegradable scaffold. These include microcarriers made from naturally occurring polymers, non-limiting examples of which include (among others) fibrin, casein, serum albumin, collagen, gelatin, lecithin, chitosan, alginate, or polyamino acids such as polylysine.

[0125] In some embodiments, the biodegradable microcarriers are made of synthetic polymers, non-limiting examples of which include (among others) polylactide (PLA), polyglycolic acid (PGA), poly(lactide-co-glycolic acid) (PLGA), poly(caprolactone), poly(p-dioxanone trimethylene carbonate), polyhydroxyalkanoates (e.g., poly(hydroxybutyrate), poly(ethyl glutamate), poly(DTH iminocarbonyl (bisphenol A imino carbonate), poly(orthoester) and polycyanoacrylate).

[0126] In some embodiments, the microcarriers comprise a hydrogel, which is typically a water-filled hydrophilic polymer network. Hydrogels have the advantage of selectively triggering polymer swelling. Depending on the composition of the polymer network, the swelling of the microparticles can be triggered by a variety of stimuli, including pH, ionic strength, heat, electricity, ultrasound, and enzyme activity. Non-limiting examples of polymers that can be used in hydrogel compositions include, among others, those formed from poly(lactide-co-glycolic acid) polymers; poly(N-isopropylacrylamide); poly(methacrylic acid-grafted polyethylene glycol); polyacrylic acid and poly(oxypropylene-co-ethylene glycol); and natural compounds such as chondroitin sulfate, chitosan, gelatin, fibrinogen, or mixtures of synthetic polymers with natural polymers, such as chitosan-poly(ethylene oxide). The polymers can be reversibly or irreversibly crosslinked to form gels adaptable to the formation of three-dimensional tissues.

[0127] In some embodiments, the microcarriers or beads used in this invention are composed entirely or partially of dextran.

[0128] In some implementations, cardiomyocyte differentiation takes place in two-dimensional or three-dimensional culture.

[0129] In some implementations, cardiomyocyte differentiation takes place in suspension culture or adherent culture.

[0130] In some embodiments, cardiomyocytes express maturity markers approximately 4 weeks after differentiation. In some embodiments, cardiomyocytes express maturity markers approximately 5 weeks after differentiation. In some embodiments, cardiomyocytes express maturity markers approximately 6 weeks after differentiation. In some embodiments, cardiomyocytes express maturity markers more than approximately 6 weeks after differentiation.

[0131] Markers of cardiomyocyte maturation include (as a non-limiting example) CAS12, S100A4, CASQ1, ADRB1, ADRB2, ATP2A2, RYR2, PLN, JPH2, CAMK2D, ATP1A3, KCNJ2, CACNA2D1, KCNQ1, SCN5A, KCNE1, SLC8A1, KCNH2, SCN4B, KCNE5, MYH6, MYL2, TNNI3, MYM2, MYH7, TPM1, MYL3, TNNC1, TNNT2, ACTC1, LPL, ACOX1, PPARA, PPARD, ACAT1, ACADVL, DGAT1, PPARGC1A, HADHB, and ACSL1. In some embodiments, maturation markers include MYL2, MYH7, and / or KCNQ1.

[0132] In some embodiments, cTnT-positive cells are observed 8 days after differentiation. In some embodiments, after at least 8 days of differentiation, cTnT-positive cells constitute at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the PSCs, or any range between any two percentages described above or herein. In some embodiments, after 9 days of differentiation, cTnT-positive cells constitute at least 80% of the PSCs.

[0133] Stem cells are undifferentiated cells capable of indefinite self-renewal and maintaining their undifferentiated state. Unlike embryonic stem cells, which can only be isolated from the inner cell mass of the blastocyst, adult stem cells have three known accessible sources: bone marrow (requiring bone drilling), adipose tissue (obtained through liposuction), and blood (from which cells can be extracted along with other cells). As used herein, the term "pluripotent stem cell" refers to a cell capable of producing all cell types of an organism (i.e., cells derived from any of the three germ layers). On the other hand, pluripotent stem cells can differentiate into several cell types, but only into those cell types of closely related cell families, typically those derived from the cell type of their organ of origin. Most adult stem cells are pluripotent, but small quantities of pluripotent adult stem cells can be obtained from the umbilical cord or other tissues. Cell sources used for cell therapy include stem cells such as embryonic stem cells (ESCs), adult stem cells, and induced pluripotent stem cells (iPSCs).

[0134] In some embodiments, the PSCs used in the methods described herein are human PSCs (hPSCs), and in some embodiments, the human PSCs are induced pluripotent stem cells (hiPSCs) or human embryonic stem cells (hESCs).

[0135] Physical culture conditions include (as a non-limiting example) the cell culture environment (e.g., adherent culture versus suspension culture, or two-dimensional culture system versus three-dimensional culture system), the pH of the culture medium, the gas concentration (e.g., CO2 concentration, O2 concentration) and temperature in the incubator.

[0136] There are two basic systems for growing cells in culture: monolayers on artificial substrates (i.e., adherent culture) or free-floating cells in a culture medium (suspension culture). With the exception of hematopoietic cell lines and a few other cell types, most vertebrate-derived cells are anchor-dependent and must be cultured on suitable substrates that have been specially treated to allow cell adhesion and spread (i.e., tissue culture treatment). However, many cell lines can also be adapted for suspension culture.

[0137] In some embodiments, the PSC culture is a cell-adherent layer. In some embodiments, the cell layer is grown in a two-dimensional culture system or on microcarriers.

[0138] In addition to surface treatment for tissue culture, cells may need to be grown on coated surfaces to enhance or improve their adhesion and / or spreading (i.e., using coatings). "Coating," as an additional surface treatment, represents all additional modifications made to improve cell adhesion beyond the standard plasma or corona treatment performed by the manufacturer on all cell culture plastics. Typically, coating is done using proteins or peptides. A variety of proteins can be used to coat tissue culture-treated culture dishes, including poly-L-lysine, poly-D-lysine, polyornithine, gelatin, type I collagen, type IV collagen, fibronectin, laminin, hydrin, osteopontin, fibronectin domains, and Matrigel. TM (Basement membrane extract containing multiple components of the extracellular matrix and growth factors), collagen gel, alginate gel, and lactate gel.

[0139] In some implementations, PSCs are cultured on a coated surface, including a laminin coating.

[0140] Physical culture conditions include the gas concentration in the incubator. Cell cultures are typically incubated in a normal atmosphere with 15-22% oxygen and 5% CO2 for expansion and seeding. In some embodiments, PSCs are grown in a humidified atmosphere with approximately 5% CO2 and normoxic conditions (not hypoxic O2 concentration). While hypoxic culture conditions are generally considered to support stem cell performance, in this method, PSCs are cultured under non-hypoxic conditions. As used herein, “normoxic” conditions refer to culture conditions that include atmospheric O2 concentration (e.g., approximately 15-25% O2). As used herein, hypoxic conditions are characterized by a lower oxygen concentration compared to the oxygen concentration of ambient air (approximately 15%-25% oxygen).

[0141] Chemical culture conditions include (as a non-limiting example) agents or molecules added to the culture medium to achieve the desired effect (i.e., differentiation of PSCs into cardiomyocytes). The terms "agent" and "molecule" are used interchangeably and include (as a non-limiting example) small molecules (including small molecules that do not have optimal cell permeability), lipids, nucleosides, nucleotides, nucleic acids, polynucleotides, oligonucleotides, antibodies, toxins, negatively charged polymers, and other polymers such as proteins, peptides, hormones, carbohydrates, or polyamines.

[0142] Unless otherwise stated, pluripotent stem cells are maintained in stem cell culture media suitable for the culture and proliferation of pluripotent stem cells. Non-limiting examples of such suitable culture media include, as a non-limiting example, StemMACS iPS-Brew XF (StemMACS iPS-Brew XF medium). For cardiomyocyte differentiation, pluripotent stem cells are switched to a “defined medium.” As used herein, the term “basal medium” generally refers to a basal medium without any additives (e.g., basal medium refers to a commercially available medium). Basal media typically include water, nutrients, salts, and amino acids, but without additives or supplements. Common additives may be added to basal media to obtain a “supplemented basal medium.” Non-limiting examples of supplements include, as a non-limiting example, insulin or ascorbic acid. The basal medium can also be “completed” with specific signaling molecules, such as those determined by the user as necessary to achieve a specific goal using cell culture, such as, for example, driving the differentiation of a target cell type into a target cell type. Non-limiting examples of basal media supplemented with specific signaling molecules include ROCK inhibitor media containing Y-27632. Such complete basal media may be referred to as "final," "complete," or "cell-specific" media.

[0143] Such basic or supplemental culture media for cardiomyocyte generation can then be prepared with target small molecules as needed.

[0144] In some embodiments, the culture medium is Knockout-DMEM or IMDM. In some embodiments, the culture medium is StemMACS iPS-Brew XF. In some embodiments, the culture medium is a formulation of Knockout-DMEM, IMDM, StemMACS iPS-Brew XF, or a related basal medium supplemented with growth factors, cofactors, cytokines, activators, or inhibitors. In some embodiments, the culture medium is a basal medium, a supplemented basal medium, a defined medium, a final medium, a complete medium, or a cell-specific medium.

[0145] The following provides examples of methods for inducing PSC differentiation into cardiomyocytes for the aforementioned applications. These examples are provided to further illustrate embodiments of the invention but are not intended to limit the scope of the invention. While these examples represent typical methods that may be used, other procedures, methods, or techniques known to those skilled in the art may be used alternatively.

[0146] Example

[0147] The present invention is further illustrated by the following non-limiting embodiments: Example 1

[0148] Design of cardiomyocyte differentiation program

[0149] During the iterative developmental process, a novel combination of factors that promotes cardiac differentiation generates cardiac progenitor cells and cardiomyocytes from pluripotent stem cells (PSCs).

[0150] The cardiomyocyte differentiation protocol detailed here consists of two main phases designed to closely mimic the natural developmental process from cardiac mesoderm to fully differentiated cardiomyocytes. Initially, the protocol employs a combination of mesodermal inducing factors, specifically BMP and WNT, along with activators of the FGF and TGF-β signaling pathways, to transform pluripotent stem cells into cardiac mesoderm. This phase is carried out in an insulin-rich medium and is intended to last from one to several days, optimally two days, to establish an environment conducive to mesodermal specialization.

[0151] Following mesodermal induction, the method transitions to a critical differentiation phase, marked by the strategic replacement of a portion of the culture medium with a formulation containing WNT pathway inhibitors. This conversion is crucial for guiding early cardiac mesoderm towards differentiation into terminal cardiomyocytes. This phase lasts for approximately one to several days, comparable to the initial induction phase, with an optimal duration of two days, thereby promoting the maturation of precursor cells into functional cardiomyocytes.

[0152] This approach, based on a deep understanding of cardiac development and cellular signaling, effectively guides pluripotent stem cells through a simulated developmental trajectory by leveraging the interactions of specific growth factors and signaling pathways. Introducing partial culture medium replacement at key transition points significantly improves the efficiency and fidelity of the differentiation process, ensuring the generation of cardiomyocytes with improved functional characteristics. This stepwise optimization method not only demonstrates the potential for generating cardiac cells in vitro for research and therapeutic applications but also provides a valuable framework for understanding and manipulating the complex pathways involved in cardiac development.

[0153] Example 2

[0154] Materials and methods for pluripotent stem cell differentiation into the heart

[0155] Table 1: Materials used for cell culture

[0156] method: Maintenance of hiPSC: hiPSCs were passaged Monday morning and Thursday afternoon at 200,000 cells per well in 6-well plates. On Monday, approximately 2.5 million cells (25,000 cells per cm²) can be expected from a single well in a 6-well plate. Scalability to other sizes, such as T75, is possible if needed. Differentiation begins Monday (before noon) from fully confluent plates.

[0157] on Monday: - Pack 3 µl iMatrix-511 per well into a 2 ml XF medium containing 10 µM Y-27632 in a 6-well plate used for hiPSC maintenance and incubate at 37°C for at least 1 hour.

[0158] - Pre-warm Accutase and approximately 10 ml of XF medium. Transfer the required volume of Accutase (1 ml per well of a 6-well plate to be harvested) into a separate tube. Add Y-27632 at a 1:1000 ratio to both solutions and mix.

[0159] - The hiPSC wells used for maintenance should be nearly confluent and generally undifferentiated. Vigorously shake the plate containing cells to collect all dead cells from the supernatant. Completely aspirate the culture medium and wash with 4 ml of PBS. Replace with 1 ml of pre-warmed Accutase containing Y-27632 and transfer to an incubator for 10–15 minutes. Most cells should detach by gently shaking the plate. If this is not the case, extend the digestion time by another 2 minutes, and so on, until the cells detach substantially on their own.

[0160] Add 1 ml of XF medium containing Y-27632 to each of the 6 wells in a 15 ml tube. Flush the cells from each well using a combination of up-and-down aspiration and rinsing 3-4 times. Transfer the cells from all wells to a 15 ml tube containing XF medium + Y-27632. Centrifuge at 300 g for 2 minutes. The supernatant should be clear, and the cells should form a firm pellet.

[0161] - Aspirate the supernatant and resuspend the cells in XF+Y medium at a rate of 2 ml per well using a 1 ml pipette, repeating the process three times. Immediately and gently transfer 8–10 µl to the counting chamber and quantify the cell titer.

[0162] - Divide 200,000 cells into each well of a newly coated 6-well plate. Transfer to an incubator and gently shake the plate inside the incubator in a manner resembling the symbol for "infinity".

[0163] Tuesday: - Feed the cells with 2.5 ml of pre-warmed XF medium per well.

[0164] Wednesday: - Feed the cells with 3 ml of pre-warmed XF medium per well.

[0165] Thursday: - Confirmed that the cells were subconfluent and completely undifferentiated. In the afternoon, coated the wells / flasks and passaged the cells at 20,000 cells per cm², the difference being that more wells may be needed to initiate cardiac differentiation next Monday. Cells for maintenance can be kept in 6-well plates, while cells for differentiation can be passaged into T75 flasks, scaling up the solution volume accordingly.

[0166] Friday: - In the afternoon, feed the hiPSC wells used for maintenance with 6 ml of XF medium per 6-well plate over the weekend. For other specifications (such as T75), scale up accordingly.

[0167] Small-scale cardiac 3D differentiation occurs during embryonic embryonic (EB) formation: on Monday: - Confirm that the hiPSCs on the wells / culture flasks used for differentiation are nearly or fully confluent and undifferentiated, forming a uniform and smooth surface. In a 6-well plate specification, each well requires 1.5 million to 3 million cells.

[0168] - Prepare the required amount of differentiation medium + approximately 1 / 3 volume for washing and resuspension steps - approximately 3 ml per 6-well plate to be started. Scale up or down proportionally accordingly: o Knockout™ DMEM (Knockout™ DMEM culture medium) o 1×ITS o PSG or only Gln or Glx o 250 µM 2-phosphoascorbic acid (from 250 mM stock solution) o 0.05% (w / v) HSA (from 10% stock solution) o 10 µM Y-27632 (stock solution 1:1000) o 5-10 ng / ml FGF2 (from 10 µg / ml stock solution) o 5-10 ng / ml Activator A (from 10 µg / ml stock solution) o 3-5 ng / ml BMP4 (from 1 or 10 µg / ml stock solution) o 0.5 µM CHIR99021 (from 1 or 3 mM stock solution) - Mix thoroughly and equilibrate to 37°C along with Accutase containing 10 µM Y-27632 (1 ml per 6-well plate to be harvested). Individual factors may also be added later (i.e., to individual samples / wells), or more than one master mixture may be prepared for several experimental conditions to be started, for example, by varying the BMP dose while keeping the CHIR99021 concentration constant.

[0169] Harvest iPSCs as you would for passage, digesting them with Accutase for 20–25 minutes after thorough washing with PBS (2×). After this incubation period, cells should detach from the plate spontaneously, requiring minimal shaking or aspiration. In each well / flask to be harvested, aspirate and retract three times to dissociate cell aggregates into single cells, then transfer to centrifuge tubes containing an equal volume of differentiation medium. Centrifuge at 300 g for 2 minutes.

[0170] - Ensure the supernatant is clear, then remove it. Resuspend the cells in differentiation medium by pipetting up and down 2-3 times per well (9 cm²) of the 6-well plate to be harvested.

[0171] - Centrifuge and resuspend the cells again as described above.

[0172] - Use a NucleoCounter (cell counter) to determine the viable cell titer. Adjust the cell titer and total volume as follows: Adjust to 750,000-1,500,000 cells per ml.

[0173] o 2 ml is needed for each 6-well plate (approximately 9 cm²).

[0174] - Dispense 2 ml per well into a standard 6-well tissue culture plate and incubate overnight on a Thermo Fisher Scientific or Heidolph wave-shaking incubator.

[0175] Tuesday: - Confirm that the cells have formed EB-like aggregates with smooth surfaces and that the culture contains relatively few individual floating cells; otherwise, it indicates poor starting conditions.

[0176] Wednesday: - Prepare basal differentiation medium containing the WNT inhibitor C-59 (approximately 0.5 ml per 6-well plate for differentiation): o Knockout™ DMEM o PSG or only Gln or Glx o 250 µM 2-phosphoascorbic acid (from 250 mM stock solution) o 0.05% (w / v) HSA (from 10% stock solution) o 2 µM C-59 (from 2 mM stock solution) - Mix thoroughly and equilibrate to 37°C.

[0177] - Remove the differentiation plate from the incubator. In the cell culture hood, tilt the plate at approximately 45° and let it stand for 0.5–1 minute. Then, carefully aspirate 25% of the culture medium using a 1 ml pipette without disturbing the aggregates that have settled at the bottom.

[0178] Add differentiation medium to 2 ml (depending on how much was aspirated in the previous step) and return to the wave shaker.

[0179] Friday: - Prepare the basic differentiation medium as described above (although C-59 is not used, use IMDM containing SB43 (Op178); 2 ml is required for each 6-well plate for differentiation), mix thoroughly and equilibrate to 37°C.

[0180] Remove the old culture medium from the differentiation wells and add 2 ml of fresh basal differentiation medium to the cells.

[0181] - Put it back on the wave rocker and incubate it over the weekend.

[0182] The following Monday and thereafter: - Cell aggregates should exhibit spontaneous pulsation by day 7 at the latest and be able to be analyzed for cardiac marker expression, or be maintained in culture for a longer period by periodically changing the medium. Overall cardiac differentiation efficiency can also be assessed after day 7 (i.e., day 8 or 9), although this should be consistent across different experiments.

[0183] Small-scale cardiac 3D differentiation following EB formation: The difference between this procedure and the one described above is that EB is first prepared in iPSC medium. Then, differentiation is initiated the next day using the prepared EB, which may have an advantage in terms of robustness.

[0184] on Monday: - Confirm that the hiPSCs on the wells / culture flasks used for differentiation are nearly or fully confluent and undifferentiated, forming a uniform and smooth surface. In a 6-well plate specification, each well requires 1.5-2 million cells.

[0185] - Prepare the required volume of iPS Brew medium + approximately 1 / 3 volume for washing and resuspension steps - approximately 5 ml per 6-well plate to be started. Scale up or down proportionally accordingly. o iPS Brew medium o 10 µM Y-27632 - Mix thoroughly and equilibrate to 37°C together with Accutase containing 10 µM Y-27632 (1 ml per 6-well plate to be harvested).

[0186] Harvest iPSCs as usual, after thorough washing with PBS (2×) and digestion with Accutase for 20-25 minutes. After this incubation time, the cells should detach from the plate on their own, requiring minimal shaking or aspiration. In each well / flask to be harvested, aspirate and retract three times to dissociate the cell aggregates into single cells, then transfer to a centrifuge tube containing an equal volume of iPSC medium.

[0187] Centrifuge at 300×g for 2 minutes.

[0188] - Ensure the supernatant is clear, then remove it. Resuspend the cells in iPSC medium containing 10 µMY-27632 by pipetting 2-3 times per well (9 cm²) of the 6-well plate to be harvested.

[0189] - Centrifuge and resuspend the cells again as described above.

[0190] - Use NucleoCounter to determine the viable cell titer. Adjust the cell titer and total volume as follows: Adjust to 750,000-1,000,000 cells per ml.

[0191] o 2 ml is needed for each 6-well plate (approximately 9 cm²).

[0192] - Dispense 2 ml per well into a standard 6-well tissue culture plate and incubate overnight on a Thermo Fisher Scientific or Heidolph wave-shaking incubator.

[0193] Tuesday: - Confirm that the cells have formed EB-like aggregates with smooth surfaces and that the culture contains relatively few individual floating cells; otherwise, it indicates poor starting conditions.

[0194] - Prepare mesotherapy induction medium (2 ml per well): o Knockout™ DMEM o 1×ITS o PSG or only Gln or Glx o 250 µM 2-phosphoascorbic acid (from 250 mM stock solution) o 0.05% (w / v) HSA (from 10% stock solution) o 5 ng / ml FGF2 (from 10 µg / ml stock solution) o 5 ng / ml activator A (from 10 µg / ml stock solution) o 3-5 ng / ml BMP4 (from 1 or 10 µg / ml stock solution) o 0.5 µM CHIR99021 (from 1 or 3 mM stock solution) - Mix thoroughly and equilibrate to 37°C.

[0195] - Remove the plate from the incubator. In the cell culture hood, tilt the plate at approximately 45° and let it stand for 0.5–1 minute. Then, carefully aspirate almost completely the culture medium using a 1 ml pipette without disturbing the aggregates settled at the bottom. Add 2 ml of the above differentiation medium and return the plate to the wave-shaking table.

[0196] Wednesday: - For 2-day mesodermal-induced variants, do not disturb the plate.

[0197] - For the 1-day mesodermal induction variant, prepare a heart-specific medium (basal differentiation medium containing the WNT inhibitor C-59; approximately 2 ml is needed per 6-well plate for differentiation): o Knockout™ DMEM o 1×ITS o PSG or only Gln or Glx o 250 µM 2-phosphoascorbic acid (from 250 mM stock solution) o 0.05% (w / v) HSA (from 10% stock solution) o 0.2-2 µM C-59 (from 2 mM stock solution) - Mix thoroughly and equilibrate to 37°C.

[0198] - Remove the differentiation plate from the incubator. In the cell culture hood, tilt the plate at approximately 45° and let it stand for 0.5–1 minute. Then, carefully aspirate the culture medium using a 1 ml pipette without disturbing the aggregates that have settled at the bottom.

[0199] - Add up to 2 ml of the above-mentioned heart-specific culture medium (depending on how much was aspirated in the previous step) and return it to the wave shaker until Friday.

[0200] Thursday: - For the 2-day mesodermal induction protocol, prepare and replace with heart-specific medium.

[0201] - For a 1-day mesodermal induction protocol, do not disturb the culture plate.

[0202] Friday: - Prepare 2 ml of basal differentiation medium per well as described above, with or without C-59 depending on the protocol: o For the 2-day mesodermal induction protocol, add C-59 o For the 1-day mesodermal induction protocol, C-59 is omitted. - Mix thoroughly and equilibrate at 37°C.

[0203] Remove the old culture medium from the differentiation well and add 2 ml of fresh cardiac-specific culture medium or basal differentiation medium to the cells.

[0204] - Return to the rocker and incubate over the weekend.

[0205] The following Monday and thereafter: - Cell aggregates exhibit spontaneous pulsation by day 7, and the expression of cardiac markers can be analyzed, or they can be maintained in culture for a longer period by periodically changing the culture medium. Overall cardiac differentiation efficiency can also be assessed after day 7 (i.e., day 8 or 9), but consistency should be maintained between experiments.

[0206] Small-scale 3D differentiation of the heart on microcarriers: Monday: - The starting point is iPSCs amplified on microbeads according to SOP RD-12, for example, the cells are seeded onto microbeads at a ratio of 200,000 cells per 6-well plate and 20 mg of microbeads on the previous Thursday.

[0207] - Harvest and count the total number of cells in a representative aliquot of the iPSC-bead culture (e.g., a complete well from several duplicate wells). Briefly: Centrifuge the beads at 300 xg for 0.5 min, aspirate the supernatant, wash with 1 volume of PBS, precipitate and wash again, then resuspend in 2 ml of pre-warmed Accutase containing Y. Transfer to a new well in a 6-well plate and incubate for 20–25 min. Dissociate the cells approximately 5 times using a 1 ml pipette, confirming single-cell dissociation under a microscope, then filter through a 40 µM cell sieve into a 50 ml tube. Rinse the sieve with a few ml of culture medium (XF medium or differentiation medium described below). Centrifuge at 300 xg for 2 min and resuspend the cells in the selected medium containing Y. Assuming 100% cell recovery on the beads, calculate the volume of the original iPSC-bead suspension corresponding to a given number of cells.

[0208] - During the Accutase digestion step in the previous step, prepare the required amount of differentiation medium plus approximately 50% of the amount used for washing and resuspension steps - approximately 3 ml per 6-well plate. Scale up or down accordingly: o Knockout™ DMEM o 1 x ITS o PSG, or only Gln or Glx o 250 µM ascorbic acid 2-phosphate (from 250 mM stock solution), optional o 0.05% (w / v) HSA (from 10% stock solution), optional o 5-10 ng / ml FGF2 (from 10 µg / ml stock solution) o 5-10 ng / ml Activator A (from 10 µg / ml stock solution) o 3-5 ng / ml BMP4 (from 1 or 10 µg / ml stock solution) o 0.5 µM CHIR99021 (from 1 or 3 mM stock solution) - Mix thoroughly and equilibrate at 37°C.

[0209] Transfer the desired volume of iPSC beads to a 15 or 50 ml tube and centrifuge at 300 g for 0.5 minutes.

[0210] - Completely aspirate the supernatant, wash the iPSC beads with excess differentiation medium, and reprecipitate.

[0211] - Resuspend the iPSC-microbeads in the required volume of differentiation medium and distribute them evenly into the target wells.

[0212] - Place the culture plate on the shaker inside the cell culture incubator.

[0213] Wednesday: - Prepare basal differentiation medium containing the WNT inhibitor C-59 (approximately 2 ml per 6-well plate): o Knockout™ DMEM o PSG, or only Gln or Glx o 250 µM 2-phosphoascorbic acid (from 250 mM stock solution) o 0.05% (w / v) HSA (from 10% stock solution) o 0.2-2 µM C-59 (from 2 mM stock solution) - Mix thoroughly and equilibrate at 37°C.

[0214] - Remove the differentiation plate from the incubator. In a cell culture laminar flow hood, tilt the plate at approximately 45° and let it stand for 0.5–1 minute. Then, carefully aspirate the culture medium using a 1 ml pipette, being careful not to disturb the microbeads at the bottom. It may not be necessary to completely replace the old culture medium; partial replacement may suffice.

[0215] Add up to 2 ml of the above differentiation medium (depending on the amount extracted in the previous step) and return it to the shaker.

[0216] Friday: - Prepare the basic differentiation medium as described above (but without C-59 - 2-4 ml per 6-well plate for differentiation), mix thoroughly, and equilibrate at 37°C.

[0217] Remove the old culture medium from the differentiation wells and add 2-4 ml of fresh basal differentiation medium to the cells.

[0218] - Return to the rocker and incubate over the weekend.

[0219] The following Monday and thereafter: - Cell-microbeads exhibit spontaneous pulsation by day 7, and the expression of cardiac markers can be analyzed, or they can be maintained in culture for a longer period by periodically changing the culture medium. Overall cardiac differentiation efficiency can also be assessed after day 7 (i.e., day 8 or 9), but consistency should be maintained between experiments.

[0220] Maintenance of differentiated cardiomyocytes: - For 3D, after differentiating into cardiomyocytes, the cells can be further maintained under simple defined conditions: o IMDM basal medium o ITS o PSG (or only Gln or Glx) o 250 µM AscP o 0.05% HSA - 3D aggregates can also dissociate into single cells in the presence of Y-27632 and be re-coated into the above culture medium (containing Y-27632 on day 1) to reform 3D aggregates.

[0221] - For 2D and 3D CM aggregates, they can be dissociated into single cells in the presence of Y-27632 and re-coated into the above-mentioned culture medium (containing Y-27632 on day 1) on iMatrix-511 (1x) coated plates.

[0222] Analysis of cardiac differentiation efficiency using FACS: - Prepare the following solutions on days 7-9 of differentiation: o PEB buffer (stable at 4°C for 4 weeks): Add 0.5 g BSA (final concentration 0.5%) and 200 µl 0.5 M EDTA (final concentration 2 mM) to 100 ml PBS (- / -).

[0223] o Fixation / permeation solution (prepare fresh): 1 volume of fixation / permeation solution 1 + 3 volumes of fixation / permeation solution 2 - 0.5 ml per sample, keep at low temperature.

[0224] o Permeation buffer (prepare fresh): 1 volume of 10x permeation buffer + 9 volumes of distilled water - 2.1 ml per sample.

[0225] Preheat Accutase (containing 10 µM Y-27632) to 37°C.

[0226] - Harvesting cells: Completely aspirate the culture medium and transfer the EB to a 1.5 ml tube. Wash with 0.5–1 ml PBS.

[0227] Centrifuge at 400 xg for 2 minutes and remove the supernatant.

[0228] Replace with 0.5 ml of preheated Accutase containing Y-27632 and transfer to an incubator to incubate on a vortex mixer for 20 minutes.

[0229] Afterward, pipette up and down twice; the cells should be single-celled. If this is not the case, extend the digestion time by 2 minutes.

[0230] The reaction was terminated with 500 µl of serum-containing culture medium and centrifuged at 400 xg for 2 minutes.

[0231] If there are clumps inside, filter the cells through a 20-40 µm sieve.

[0232] - Fix and stain the cells: o Remove the supernatant, wash the cells with at least 1 ml of PEB buffer, and centrifuge at 400 xg for 2 minutes.

[0233] o Resuspend the cells in 0.5 ml of cold, freshly prepared fixation / permeabilization solution.

[0234] Mix thoroughly and incubate in a refrigerator (2-8°C) on a rotisserie (MACSmix) for 30 minutes.

[0235] Centrifuge at 400 xg for 2 minutes.

[0236] o Remove the supernatant, add 0.5 ml of 1x permeation buffer, and centrifuge at 400 xg for 2 minutes.

[0237] o Remove the supernatant and resuspend in 100 µl 1x permeabilization buffer + 2 µl cTNT-FITC or isotype control.

[0238] Mix thoroughly and incubate in a refrigerator (2-8°C) on a rotisserie (MACSmix) for 30 minutes.

[0239] Add 1 ml of 1x permeation buffer and centrifuge at 400 xg for 2 minutes.

[0240] o Remove the supernatant and resuspend the cell pellet in 300 µl of PEB buffer for analysis on the FACS instrument.

[0241] - Analyzing cells on MACSQuant: o Turn on the machine or launch the software via the touchscreen.

[0242] After logging in, click the button in the upper right corner > Data Acquisition Mode, and let the machine warm up for about 30 minutes.

[0243] o View > Hardware > Lens and Inspection: Confirmed that the blue laser has stabilized at approximately 37°C.

[0244] o Run microbead calibration: Add one drop of microbeads (stored at 2-8°C) to the FACS tube and place it in the holder; press the barcode reader symbol in the upper right corner and scan the barcode on the storage bottle containing the calibration microbeads > The calibration run will start and end automatically.

[0245] Optional: Click the droplet button in the lower right corner to rinse.

[0246] o Open > Instrument Settings > Select the appropriate template (FSC lin at 380 / SSC lin at 634 / B1hlog at 400 / Trigger FSC at 17.30).

[0247] o Open > Workspace > Select the appropriate template for drawing SSC-A vs. FSC-A (P1) / SSC-A vs. SSC-H (P2, gated with P1) / Counts vs. FITC channel (gated with P2) / SSC-H vs. FITC channel (gated with P2).

[0248] o Project > Enter Experiment ID.

[0249] o Settings > P2.

[0250] o Events > 50,000.

[0251] o Define the sample and loading volumes (e.g., 300 µl and 200 µl, respectively).

[0252] Define the sample ID; vortex and place the first sample into the holder, then click the start button in the lower right corner. Repeat this process for the remaining samples.

[0253] o Cleaning: Inject approximately 2 ml of cleaning solution into the FACS tube and start the cleaning procedure after pressing the drop button in the lower right corner.

[0254] Click the button in the upper right corner > Turn off the instrument.

[0255] Abbreviations and Standard Reagents:

[0256] Example 3

[0257] Cardiomyocytes differentiated from human pluripotent stem cells

[0258] Differentiation of induced pluripotent stem cells (iPSCs) into cardiomyocytes recreates the various stages of early in vivo heart development, guiding pluripotent stem cells (PSCs) first into the mesoderm and then through heart-specification to form cardiomyocytes. For many years, various strategies have been employed to generate cardiomyocytes from human PSCs (hPSCs). It has been determined that activation of the WNT pathway with an appropriate dose of the small molecule CHIR99021 can induce cardiac mesoderm (PMID: 22645348, 23257984). Similarly, a protocol utilizing bone morphogenetic protein (BMP) has also been employed (PMID 18432194). These pathways are known to synergistically enhance cardiac fate induction. Notably, the addition of BMP4 has been found to significantly enhance WNT signaling by regulating key target genes in the early stages of differentiation. Therefore, when WNT and BMP agonists are used in combination, their effective doses are reduced (BMP4 below 10 ng / ml, CHIR99021 below 2 µM). In addition, FGF2 and activin A act as “co-factors” in this process, improving efficiency and consistency between experiments, although their simultaneous activation is not considered necessary.

[0259] Mesodermal-induced cardiac specialization is achieved by inhibiting the WNT pathway, which can be induced in vitro by pharmacological inhibitors such as IWP2, IWR1, and C-59 (PMID: 26748419, PMID: 21737789, PMID:24930130). The criticality of this inhibitory step immediately after WNT activation has been emphasized by Rao et al. (Rao, Jyoti et al. "Stepwise Clearance of Repressive Roadblocks Drives Cardiac Induction in Human ESCs." Cell stem cell vol. 18,3 (2016): 341-53. doi:10.1016 / j.stem.2015.11.019).

[0260] While some protocols have achieved differentiation efficiencies exceeding 90%, consistency between independent experiments remains a challenge. Even under seemingly constant conditions, discrepancies in results highlight the urgent need for methodological improvements to enhance robustness, which is crucial for therapeutic applications where inconsistencies can lead to significant delays.

[0261] Co-stimulation of the BMP and WNT pathways (optionally combined with FGF / ERK and TGFβ / SMAD cascade activation) has been shown to be more effective than WNT stimulation alone in inducing cardiac mesoderm. This improved approach aims to mitigate sensitivity to cell titer fluctuations and improve reproducibility. The addition of ascorbate and albumin to the differentiation medium has beneficial effects on reproducibility. A key step in achieving high reproducibility is performing only a partial medium change during the transition from WNT activation to inhibition, unlike the conventional full medium change aimed at reversing signaling pathway activity.

[0262] In a systematic development process, various parameters affecting cardiac differentiation in a 3D environment were optimized. Co-stimulation of the BMP and WNT pathways, along with FGF and TGFβ signaling activators, initiated cardiac mesoderm differentiation in an insulin-containing medium for one to several days (ideally two days), followed by partial medium replacement with the addition of WNT inhibitors for terminal cardiomyocyte differentiation for another one to several days (again, ideally two days). This co-stimulation strategy was effectively applied in a 3D environment, forming the basis for comprehensive optimization of efficiency and consistency in over 100 experiments. The final protocol (initiating differentiation during rather than after 3D aggregate formation) is detailed in [reference needed]. Figure 1A A comparison with the semi-optimized version (gray dots) shows that introducing partial culture medium replacement (optimized version, blue dots) during the transition to WNT inhibition significantly improves robustness. Figure 1B As shown. Minor modifications, such as adjusting the culture medium replacement interval and adding ascorbic acid, can help establish robust methods on a smaller scale, such as... Figure 1C and Figure 1B As shown by the blue dots in the image.

[0263] Figure 2 This indicates that 25% or less of the culture medium can optimize consistency between experiments, highlighting the critical nature of partial culture medium replacement for establishing robust methods and overcoming batch-to-batch variability.

[0264] Initially, BMP4 and CHIR99021 were identified as fundamental inducing agents for cardiac mesoderm. Titration experiments showed that their combined application produced high differentiation efficiency (verified by cardiac troponin C staining), in contrast to the results of WNT activation alone. Figure 3A However, reproducing these promising results was challenging. Further investigation identified cell titer as a key variable. Figure 3B Even a moderate reduction in these concentrations can significantly impact differentiation efficiency, highlighting the necessity of consistent parameter control. The heatmap representation of the grid titration of BMP4 and CHIR99021 concentrations used to optimize cardiac mesodermal induction is shown below. Figure 3CAs shown, activation of the WNT pathway alone is less effective than co-stimulation of the BMP and WNT pathways.

[0265] Introducing FGF2 and activin A at optimized doses in a costimulatory mixture can moderately improve cardiac differentiation efficiency. Figure 4A Crucially, the four-pathway stimulation strategy enhanced the robustness of the protocol by reducing the impact of changes in cell titer. Figure 4B ).

[0266] Figure 5 Comparison of various method variations further confirms that co-stimulation of the BMP and WNT pathways consistently yields superior and more uniform results, although high efficiency can also be achieved under certain conditions with WNT stimulation alone. This flexibility in the timing of signal stimulation is further confirmed by Figure 6, demonstrating the adaptability of this approach to different basal media, including Knockout-DMEM and IMDM.

[0267] The key role of WNT pathway inhibition is... Figure 7 It is emphasized that C-59 has a wide effective concentration range for cardiac specificity (standard: final concentration 0.5 µM).

[0268] The necessity of "non-specific" additives (such as L-ascorbic acid (or 2-phosphate-L-ascorbic acid) and albumin) for efficient cardiac differentiation, as Figure 8 As shown, this illustrates the scenarios in which these compounds are indispensable.

[0269] Finally, iPSC-derived cardiomyocytes initially exhibit immature gene expression characteristics. Figure 9A ), and then transition to genes encoding the late myosin light and heavy chains ( Figure 9B and Figure 9C The more defined sarcomere structure indicates that the default fate of the ventricle has matured.

[0270] While preferred embodiments of the invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Many variations, modifications, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in carrying out the invention. The following claims are intended to define the scope of the invention and should accordingly cover the methods and structures within the scope of these claims and their equivalents.

Claims

1. A method for inducing pluripotent stem cells (PSCs) to differentiate into cardiomyocytes, comprising: a) Expose PSCs to a culture medium for one or more days, wherein the culture medium comprises a WNT signaling pathway activator and: (i) Activators of the bone morphogenetic protein (BMP) signaling pathway; (ii) Optional FGF / ERK signaling pathway activators; as well as (iii) Optionally, TGF-β signaling pathway activators; as well as b) Replace part of the culture medium in a) with a medium containing an inhibitor of the WNT signaling pathway, and culture for one or more days. This induces the PSCs to differentiate into cardiomyocytes.

2. The method according to claim 1, wherein the FGF / ERK signaling pathway activator is FGF2.

3. The method according to claim 2, wherein the concentration of FGF2 ranges from about 2.5 ng / ml to 20 ng / ml.

4. The method according to claim 1, wherein the TGF-β signaling pathway activator comprises activin A.

5. The method of claim 4, wherein the concentration of activator A ranges from about 2.5 ng / ml to 20 ng / ml.

6. The method according to claim 1, wherein the volume of the culture medium replaced in b) is about 10%, 25%, 50% or 75% of the culture medium in a).

7. The method according to claim 6, wherein the volume of the culture medium replaced in step b) is about 25% of the volume of the culture medium in a).

8. The method according to claim 1, wherein the WNT signaling pathway activator comprises CHIR99021.

9. The method of claim 1, wherein the BMP comprises BMP4.

10. The method of claim 1, wherein the culture medium from a) and / or b) further comprises ascorbate and / or albumin, and optionally L-glutamine.

11. The method of claim 10, wherein the culture medium optionally comprises one or more salts of 2-phosphate-L-ascorbate.

12. The method of claim 1, wherein the contact in a) is for at least 2 days.

13. The method of claim 1, wherein the culture in b) is for 2 to 5 days.

14. The method according to claim 1, wherein the WNT signaling pathway inhibitor is selected from IWP2, IWR1 or C-59.

15. The method of claim 14, wherein the concentration of the WNT signaling pathway inhibitor is at least 0.1 µM.

16. The method of claim 1, wherein the cardiomyocytes express maturity markers after approximately 6 weeks of differentiation.

17. The method of claim 16, wherein the maturity markers include MYL2, MYH7 and / or KCNQ1.

18. The method of claim 1, wherein the cardiomyocyte differentiation is carried out in a culture selected from the following: two-dimensional culture, three-dimensional culture, suspension culture, and adherent culture.

19. The method of claim 18, wherein the culture is a plate, microcarrier beads, or a mesh matrix.

20. The method of claim 1, wherein, after 9 days of differentiation, cardiac troponin T (cTnT) positive cells account for at least 80% of the PSCs.

21. The method of claim 1, wherein the culture medium from a) and b) is Knockout-DMEM or IMDM.

22. The method of claim 1, wherein the PSC is a human PSC (hPSC).

23. The method of claim 22, wherein the hPSC is a human induced pluripotent stem cell (hiPSC) or a human embryonic stem cell (hESC).

24. A method for inducing pluripotent stem cells (PSCs) to differentiate into cardiomyocytes, comprising: a) Contact PSCs with iPSC medium for at least one day, wherein the iPSC medium includes a Rho-associated kinase (ROCK) inhibitor to obtain cells cultured with a ROCK inhibitor; b) Contact the ROCK inhibitor-cultured cells with a mesotherapy induction medium for one or more days, wherein the mesotherapy induction medium comprises: (i) WNT signaling pathway activators; (ii) Bone morphogenetic protein (BMP) signaling pathway activators; (iii) Optional FGF / ERK signaling pathway activators; and (iv) Optionally, TGF-β signaling pathway activators; c) Replace part of the differentiation medium from b) with a medium containing inhibitors of the WNT signaling pathway, and culture for one or more days. This induces the PSCs to differentiate into cardiomyocytes.